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Abstract
Highly active antiretroviral therapy (HAART) contributes to metabolic disorders and the
growing prevalence of metabolic syndrome (MetS) in human immunodeficiency virus
(HIV)-infected patients. Hypertension, obesity, and hyperglycemia (components of
MetS) are risk factors for cardiovascular disease. Studies have shown that HIV patients
on HAART have a 2-fold risk of dying from MetS. There are no such studies in
Umuahia; hence the need for this study to fill this gap. Using a sample size of 192
medical records of HIV-infected patients in Federal Medical Centre, Umuahia, and
applying metabolic syndrome theory, this study examined the relationships among types
of HAART regimen, duration of HAART and hypertension, obesity, and hyperglycemia
among HIV-infected adult patients. The records were stratified into 4 by duration of
HAART. Chi-square test was used to determine associations between the nonparametric
variables, whereas multiple logistic regressions were used to estimate the odds ratios.
Odds of hypertension were more than 18-fold (OR = 18.52, 95% confidence interval [CI]
= 5.464, 42.50) at >12 months on HAART, whereas odds of obesity was more than 5-fold
(OR = 5.43, 95% CI = 2.227, 13.158) at >12 months. Odds of hyperglycemia were more
than 14-fold at >12 months compared with <12 months on HAART. Statistical
significance was achieved with duration of HAART for hypertension and hyperglycemia
(p < .05) but none with types of HAART (p < .05). Being male, older age, and duration of
HAART were associated with odds of metabolic syndrome components. This knowledge
provides a base for population-based intervention programs for the HIV-positive
population undergoing antiretroviral therapy in the Umuahia metropolis.
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Chapter 1: Introduction
Access to highly active antiretroviral therapy (HAART) significantly reduced the
rate of human immunodeficiency virus (HIV) infection-related mortality and morbidity
(Berhane, Yami, Alemseged, Yemane, Hamza, Kassim, & Deribe, 2012). The advent of
HAART in the management of HIV-positive patients in 1996 brought about a significant
reduction in the annual mortality rates in the HIV-positive population from more than
29% to less than 2% in a space of 10 years (May, Sterne, & Costagliola, 2006). However,
new concerns have arisen regarding the adverse effects of HAART on the metabolic
system of HIV-infected patients (Muhammad, Sani, & Okeahialam, 2013). According to
Muhammad et al., observed metabolic abnormalities such as hyperlipidemia, insulin
resistance, high blood pressure, and fat redistribution constitute major risk factors for
cardiovascular disease (CVD). These abnormalities are said to be components of the
metabolic syndrome (MetS). However, variation exists in the risk factors by population
characteristics and racial differences (Grundy, Cleeman, Daniels, Donato, Eckel, et al.,
2005; Ngatchoua, Lemogouma, Ndobob, Yiagnignib, Tiogoub, et al., 2013).
I examined the relationship among HAART regimen and hypertension, obesity,
and diabetes as metabolic syndrome components, and I examined the association among
duration of HAART regimen and hypertension, obesity, and diabetes as metabolic
syndrome components. The incidence of metabolic syndrome and CVD in the HIVpositive population can be reduced and prevented through informed population–based
intervention programs if the right attention is drawn to these modifiable risk factors.
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In this chapter, I introduce the study topic and the overview of the study. In the
first section of this chapter, I summarize relevant, recent literature relating HAART with
hypertension, obesity, and diabetes as metabolic syndrome components. I also provide
insights into the problem addressed in this study, the purpose of the study, research
questions, and the hypotheses. In the second section, I introduce the theoretical concepts
that formed the framework of the study; I summarize metabolic syndrome theory; and I
describe the nature of research, definitions, scope of the study, delimitations, and
limitations. I also highlight the significance of this study for the advancement of public
health through positive social change.
Background
HIV is a lentivirus of the retrovirus family. The acquired immunodeficiency
syndrome (AIDS) virus infects the individual through various routes of transmission and
then invades the host’s immune system (Agyemang-Yeboah & Nkum, 2012). The
infected person’s immune system is thus compromised, thereby creating room for lifethreatening opportunistic infections (Agyemang-Yeboah & Nkum, 2012). According to
Agyemang-Yeboah & Nkum, the virus has the potential of surviving in body fluids and
be transmitted from person to person.
Using anti-HIV drugs in the treatment of individuals infected with HIV is termed
antiretroviral therapy (World Health Organization [WHO], 2014). The therapy is a
cocktail of at least three drugs that reduces or suppresses the replication of the HIV. The
combined therapy is popularly called HAART (WHO, 2014). A combination of three
drugs is used to reduce the possibility of the virus developing resistance to the drugs
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(WHO, 2014). Using cocktail of medicines confers the unique quality that can stop the
HIV disease progression (WHO, 2014). The drug combination reduces the rates of
disease progression and mortality in this population of patients, thereby improving the
quality of life of these patients (WHO, 2014). Using HAART in HIV infection
management has led to increased prevalence of diabetes mellitus, insulin resistance,
lipoatropy, fat redistribution, dyslipidemia, hypertension, hepatic steatosis (Currier,
2014), and arterial stiffness (Ngatchou et al., 2013). These metabolic syndrome
components in conjunction with other factors according to Stein and Hsue (2012)
increase the risk for CVD.
According to Zhou, Wang, and Yu (2014), common pathways exist between CVD
and metabolic syndrome that are shared by patients with metabolic syndrome. These
pathways include defective glucose metabolism, increased oxidative stress,
hypercoagulability, and endothelial damage. In addition, hypertension and insulin
resistance are components of metabolic syndrome that most times coexist (Zhou,
Schulman, & Zeng, 2012). Furthermore, insulin also induces vasorelaxation through
stimulation of nitric oxide in the endothelium in addition to its metabolic effects (Zhou et
al., 2012). Similarly, Schulman and Zhou (2009) demonstrated that insulin resistance
contributed to the development of CVD and hypertension in cardiovascular tissues.
Several studies in the United States, Europe, and Canada investigated the
incidences of CVD. The studies compared CVD in HIV-infected patients and persons
without HIV infection (Chow, Regan, Feske, Meigs, Grinspoon et al., 2012) and CVD in
HIV-infected patients on HAART and HIV-infected patients not on HAART (Durand,
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Sheehy, Baril, Lelorier, & Tremblay, 2011; Freiberg, Chang, Kuller, Skanderson, Lowy
et al., 2013; Lang, Mary-Krause, Cotte, Gilquin, Partisani et al., 2010). Their findings
confirmed increased rates of cardiovascular events in HIV-infected patients who took
HAART. In a similar study, the risk of heart attack and stroke was two to four times
increased by hyperglycemia—a component of metabolic syndrome (Alberti, Eckel,
Grundy, Zimmet, Cleeman et al., 2009). The management of chronic diseases such as
diabetes mellitus, hypertension, and CVD in HIV-positive patients adversely affects the
quality of life and increase the financial burden on the patient as well as the health care
system (Centers for Disease Control and Prevention [CDC], 2013).
HAART and Metabolic Syndrome Prevalence
Due to the adverse metabolic effects such as increased blood pressure,
dyslipidemia, and insulin resistance associated with HAART regimen, there have been
reported cases of increased incidences of cardiovascular disorders in this group of the
population (Guaraldi, Stentarelli, Zona, Orlando, Carli et al., 2010; Palios, Kadoglou, &
Lampropoulos, 2012). Guaraldi et al. reported a 26% increase in risk for myocardial
infarction in their study. Other reported adverse effects of HAART include arterial wall
stiffness (Ngatchou et al., 2013) and coronary artery calcium (CAC) (Guaraldi et al.,
2010). The reported adverse effects of HAART play a role in the development of
atherosclerosis and increased risk for myocardial infarction (Guaraldi et al., 2010;
Ngatchou et al., 2013). The growing concern for increasing prevalence of metabolic
abnormalities and risk of CVD among HIV-positive patients on HAART has necessitated
several observatory cohort studies (Durand, Sheehy, Baril, Lelorier, & Tremblay, 2011;
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Guaraldi et al., 2010; Muhammad et al., 2013; Ngatchou et al., 2013; Omech, Sempa,
Castelnuovo, Opio, Otim et al., 2012) to determine the prevalence of metabolic
syndrome. The studies also established the relationship between HAART and metabolic
syndrome components, and the incidence of CVD among the HIV-positive population.
These studies on the prevalence of metabolic abnormalities and risk of CVD among the
HIV-positive population validate reports that metabolic syndrome prevalence varies by
population, race/ethnicity, and age (Muhammad et al., 2013; Ngatchou et al., 2013).
Although the prevalence of metabolic syndrome may vary by race/ethnicity and increase
with age, the studies showed that other modifiable risk factors vary within and between
populations (Razzouk & Muntner, 2009).
In the United States, data from the National Health and Nutrition Examination
Survey (NHANES) was used to monitor and estimate the U.S. population (BeltránSánchez, Harhay, Harhay, & McElligott, 2013). Increased concern regarding the
prevalence of metabolic syndrome has prompted the CDC to conduct series of crosssectional studies every 2 years to assess prevalence rate of metabolic syndrome in the
U.S. population (Beltrán-Sánchez, Harhay, Harhay, & McElligott, 2013). However, in
Nigeria there are no such continuous studies that assess the prevalence rate of metabolic
syndrome.
In the NHANES studies, during physical examinations, blood samples were
collected and analyzed to determine the presence of metabolic syndrome components
using the harmonized definition of metabolic syndrome that defined metabolic syndrome
as the presence of three or more of the metabolic syndrome components (Alberti et al.,
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2009). The results showed an estimate of 25% metabolic syndrome prevalence rate
(Mozumdar & Liguori, 2011). A similar study conducted among a British cohort of
middle-aged men estimated the prevalence of metabolic syndrome to be 26%
(Wannamethee, 2008). The studies of Mozumdar and Liguori; Wannamethee have
contributed in validating the reports that prevalence of metabolic syndrome varies
between and within populations. Razzouk and Muntner (2009); Rosolova and
Nussbaumerova (2011) also showed that there are different rates of disease progression
and that metabolic syndrome is a marker for metabolic abnormalities. Furthermore, the
studies by various researchers showed that there are arrays of designs and methods used
to determine the prevalence and presence of metabolic syndrome in various populations
(Alberti, Eckel, Grundy, Zimmet, Cleeman et al., 2009; Mozumdar & Liguori, 2011;
Muhammad et al., 2013; Ngatchou et al., 2013; Wannamethee, 2008).
The growing increase in the prevalence of metabolic syndrome and its
components has been attributed to physical inactivity, unbalanced food intake, and the
use of HAART in the HIV-positive population (Paula, Falcão, & Pacheco, 2013). Thus,
this study focused on a group of certain metabolic factors associated with risk for
cardiovascular disease. These metabolic factors include high blood pressure, obesity, and
elevated blood glucose levels, (Alberti et al., 2009). Thus, the presence of any three or
more of the five factors (elevated blood glucose levels, abnormal blood lipid levels,
elevated triglyceride, high blood pressure, and obesity) is termed metabolic syndrome
(Alberti et al., 2009). Grundy et al. (2005) defined metabolic syndrome as the presence of
at least three of the five of metabolic syndrome components: (a) elevated triglycerides
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≥150; (b) low high-density lipoprotein cholesterol <40 for men <50 for women; (c)
elevated blood pressure of ≥130/≥85 mm Hg; (d) fasting blood glucose >100 mg/dL; (e)
body mass index (BMI) of ≥30 kg/m2. However, only elevated blood pressure, elevated
blood glucose, and obesity as metabolic syndrome components were employed in the
study. Based on the guidelines of the National Cholesterol Education Program’s (NCEP)
Adult Treatment Panel (ATP) III, the following criteria were adopted in this study: (a)
elevated blood pressure of ≥130/≥85 mm Hg or treatment for hypertensive; (b) fasting
blood glucose >100 mg/dL, or antidiabetic treatment; (c) BMI ≥30 kg/m2 (Anon, 1998;
WHO, 2015).
The observations by the NCEP and other researchers (Guaraldi et al., 2010;
Ngatchou et al., 2013) reported that metabolic syndrome is a multiple component risk
factor for cardiovascular disease and it is, therefore, deserving of more attention,
especially as it concerns diet and lifestyle in the HIV-positive population.
Problem Statement
The introduction of HAART in the management of HIV infection has
significantly reduced morbidity and mortality rates in HIV-positive patients (Berhane et
al., 2012). However, HAART has created a new burden of metabolic disorders that are
risk factors for CVD in these categories of patients (Kiage, Heimburger, Nyirenda,
Wellons, Shashwatee et al., 2013).
Metabolic syndrome is a major public-health and medical challenge that is on the
increase globally (Alberti & Zimmet, 2005). In Africa, diabetes a component of MetS
affects more than 14 million people, and it is expected that by 2030, 28 million

8
individuals will be affected (International Diabetes Federation [IDF], 2011). In Nigeria,
reports showed that MetSprevalence rate among diabetic patients is more than 80%
(Okafor, 2012). According to Alberti and Zimmet, metabolic syndrome patients have
increased risk of myocardial infarction up to three- to 4-fold, of stroke up to two- to 4fold, and a 2-fold risk of dying from these metabolic syndrome components.
HAART has been linked to the development of metabolic syndromes
(Muhammad et al., 2013). According to Friis-Moller, Sabin, & Weber (2007) and
Muhammad et al., metabolic syndrome components increases the risk of cardiovascular
disease, heart attack, and stroke. Other known risk factors for metabolic syndromes
include protease inhibitors (PIs); nucleosides reverse transcriptase inhibitor(s) (Wu et al.,
2012); cigarette smoking; the effect of chronic inflammation related to the infection, and
advancing age (Steinhart & Emons, 2004). PIs target the HIV-1 PR and inhibit its
enzymatic activity thereby preventing the cleavage of the Gag and Gag-pol that bring
about the production of noninfectious virus particles (Adamson, 2012).
In response to these emerging burdens of metabolic abnormalities among HIVpositive patients treated with HAART, several researchers conducted cross-sectional
observational studies that observed that metabolic syndrome components are prevalent in
HIV-positive patients on HAART (Alvarez, Salazar, & Galindez., 2012; Berhane et al.,
2012; Hansen, Petersen, Haugaard, Madsbad, Obel et al., 2009; Muhammad et al., 2013;
Omech et al., 2012;). In Nigeria, Muhammad et al. reported 21% prevalence of metabolic
syndrome among HIV-positive patients on HAART. Wu et al. (2012) also found in their
study conducted in Taiwan that a metabolic syndrome was developed in approximately
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one quarter of HIV-infected patients on HAART. In Wu et al.’s study, 210 (26.2%) of
877 HIV-positive patients developed metabolic syndrome. The results also showed an
association among prolonged exposure to HAART, PIs; nucleoside reverse transcriptase
inhibitor(s), and metabolic syndrome OR of 1.78 (95% confidence interval [CI], 1.03–
3.07), 1.96 (95% CI, 1.13–3.42), and 1.91 (95% CI, 1.11–3.30), respectively (Wu et al.,
2012). Hansen et al. conducted a similar cross-sectional study in the department of
infectious diseases, Hvidovre Hospital, Denmark. The results of the study showed that
27% of a total of 566 HIV-positive patients treated with various antiretroviral drug
classes developed a metabolic syndrome (Hansen et al., 2009). Furthermore, Alencastro
et al. in their cross-sectional study in southern Brazil also confirmed that metabolic
syndrome was prevalent in southern Brazil. In the same vein, Friis-Moller et al.
demonstrated in their data collection on adverse events of anti HIV drugs Data Collection
on Adverse Events of Anti-HIV Drugs (DAD) study that association exists between
antiretroviral therapies and cardiac risk factors (Friis-Moller et al., 2007). This reported
association is partly responsible for the increase in the rate of myocardial infarction.
Increased rate of myocardial infarction was demonstrated by an increase in relative risk
(RR) for myocardial infarction with the use of protease inhibitor (1.16; 95% CI, 1.10–
1.23; p ≤ .001) after controlling for dyslipidemia, diabetes, and hypertension. Studies also
showed that there is a greater risk of myocardial infarction and CVD in HIV-positive
patients treated with HAART than are non–HIV-infected persons who are not on
HAART (Friis-Moller et al., 2003; Triant, Lee, Hadigan, & Grinspoon, 2007; Grinspoon,
2009). The underlying causes according to Grinspoon are multifactorial that include risk

10
factors such as the effect of chronic inflammation related to HIV infection, adverse
metabolic effects of antiretroviral therapy, and cigarette smoking (Grinspoon, 2009).
HIV infection activates the inflammatory pathways that change the endothelial
cells to prothrombotic from their phenotype, which result in increased carotid intima
thickness (Dagogo-Jack, 2008). This phenomenon occurs as a consequence of the direct
activation of the endothelial cells by HIV and explains why HIV increases the risk for
CVD (Dagogo-Jack, 2008). Similarly, in HIV-infected individuals, tumor-necrosis factor
(TNF) Receptors 1 and 2, high sensitive C-reactive protein, and abnormal fat distribution
contribute to impaired glucose homeostasis (Brown, Tassiopoulos, Bosch, Shikuma &
McComsey, 2010). Metabolic dysfunction such as dyslipidemia, lipodystrophy, insulin
resistant, and diabetes occur as a result of the administration of antiretroviral therapy
(Dagogo-Jack, 2008).
Adverse metabolisms according to Steinhart & Emons (2004) lead to the
development of hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein
cholesterol levels, high low-density lipoprotein cholesterol level, insulin resistance, and
hyperglycemia. These are components of metabolic syndrome and they present
challenges in the treatment process, and also creates a burden on the finances of these
individuals (Steinhart & Emons, 2004). Although several studies on metabolic syndrome
in HIV-positive patients on HAART, and the risk of CVD has been conducted in Brazil,
Denmark, Taiwan, the United States, Ethiopia, and Cameroon, similar studies are limited
in Nigeria. A few studies in the northeastern and northwestern Nigeria examined the
relationship between HAART and metabolic syndrome, with a view of its effect on
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cardiovascular health in HIV-positive patients (Denue, Muazu, Gashau, Mbo, and Ajayi,
2012; Muhammad et al., 2013; Ogundahunsi, Oyegunle, Ogun, Odusoga, & Daniel, O. J.,
2008). However, such studies are yet to be conducted in Umuahia metropolis. Hence, this
study sought to fill this gap in the existing literature and examine the relationship
between HAART regimen and hypertension, obesity, diabetes as metabolic syndrome
components with a view to identifying the risk of CVD among HIV-positive adults 18
years and older on HAART in this study area (Federal Medical Centre,
Umuahia,southeast Nigeria).
Purpose of the Study
The purpose of this retrospective quantitative study was to examine the
relationship among HAART regimen and hypertension, obesity, and diabetes as
metabolic syndrome components among HIV-positive patients 18 years and older, after
ruling out the presence of these three variables at baseline. I also sought to examine the
relationship among duration of HAART regimen and hypertension, obesity, and diabetes
as metabolic syndrome components after controlling for age, gender, and CD4+ cell
count. To determine the prevalence of hypertension, obesity, and diabetes as metabolic
syndrome components among HIV-positive patients 18 years and older attending the
clinic at the Federal Medical Centre, Umuahia Abia State, Nigeria, I used medical chart
reviews including baseline data.
This study’s findings will help identify cardio metabolic risk factors attributed to
the side effects of antiretroviral therapy. I hope that this study will contribute to
preventing additional burdens of chronic diseases such as hypertension, obesity, and
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diabetes in the study population through intervention programs, and I hope the findings
will help reduce the cost of health care; encourage positive, healthy lifestyles; and
improve the quality of life of HIV-positive patients on HAART.
Research Questions and Hypotheses
I attempted to answer two main research questions and sub questions, with
corresponding research hypotheses (Ha), and null hypotheses (H0) as listed below.
RQ1: Type of HAART Regimen
RQ1A: Is there an association between HAART regimen and elevated blood pressure
(hypertension) as a metabolic syndrome component among HIV-positive patients 18
years and older in Umuahia, southeast Nigeria?
H0: HAART regimen does not increase the odds of hypertension.
Ha: HAART regimen increases the odds of hypertension.
RQ1B: Is there an association between HAART regimen and obesity as a metabolic
syndrome component among HIV-positive patients 18 years and older in Umuahia,
southeast Nigeria?
H0: HAART regimen does not increase the odds of obesity.
Ha: HAART regimen increases the odds of obesity.
RQ1C: Is there an association between HAART regimen and elevated blood glucose
level (hyperglycemia) as a metabolic syndrome component among HIV-positive patients
18 years and older in Umuahia, southeast Nigeria?
H0: HAART regimen does not increase the odds of hyperglycemia.
Ha: HAART regimen increases the odds of hyperglycemia.
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RQ2: Duration of HAART Regimen
RQ2A: Is there an association between duration of HAART regimen and hypertension
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria?
H0: Duration of HAART regimen does not increase the odds of hypertension.
Ha: Duration of HAART regimen increases the odds of hypertension.
RQ2B: Is there an association between duration of HAART regimen and obesity among
HIV-positive patients 18 years and older in Umuahia, Southeast Nigeria?
H0: Duration of HAART regimen does not increase the odds of obesity.
Ha: Duration of HAART regimen increases the odds of obesity.
RQ2C: Is there an association between duration of HAART regimen and elevated blood
glucose (hyperglycemia) level among HIV-positive patients 18 years and older in
Umuahia, southeast Nigeria?
H0: Duration of HAART regimen does not increase the odds of hyperglycemia.
Ha: Duration of HAART regimen increases the odds of hyperglycemia.
Theoretical Foundation and Conceptual Framework
Epidemiological studies are prompted by observations of events and phenomena
that explore relationships between hosts (Kamanger, 2012). These could be chemical,
physiological or biological factors. Epidemiological studies focus on looking for causes
of diseases by linking exposures to risk of developing diseases (Kamanger, 2012). Thus,
investigational studies involving infectious diseases such as HIV/AIDS focus on a single
causal factor. However, the situation is different with chronic diseases that focus on the
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relationship between several factors such as environmental, host behaviors, and
physiological changes (McKenna & Collins, 2010). According to the University of
Toronto (n.d.), HIV disease is also being viewed as a chronic, long-term disease that has
been evaluated by the rising prevalence of disability among HIV-positive patients.
HIV is a multisystem infection that affects different systems of the body such as
the cardiorespiratory, the musculoskeletal, and neurological systems (University of
Toronto, n.d). HIV infection is further complicated by antiretroviral therapies including
HAART, which cause undesirable side effects, thereby affecting the day-to-day activities
and quality of life of HIV-positive patients (University of Toronto, n.d). As a result, to
prevent or delay chronic diseases attributed to the side effects of HIV infections and
antiretroviral therapy, it is recommended that intervention programs that include lifestyle
and behavioral changes be developed (CDC, n.d.).
The physiologic changes that predispose infected patients to the development of
CVD as a result of exposure to HAART are described by the metabolic syndrome theory
(American Diabetes Association [ADA], n.d.). Metabolic syndrome theory is the
foundation on which this study was based. Reaven (1988) proposed the metabolic
syndrome theory first by describing the metabolic and physiologic changes observed in
patients with diabetes type 2 diabetes mellitus (DM2) that leads to CVD. The syndrome
is based on malfunctioning of insulin in the body system that results in insulin resistance.
Furthermore, the observed association between obesity and hypertension attracted the
inclusion of increased risk of hypertension in obese individuals in the metabolic
syndrome theory. Also, Wilcox (2005) posited that changes in protein metabolism, fat
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metabolism, and elevated blood sugar levels were responsible for insulin resistance.
Thus, metabolic syndrome is characterized by elevated blood sugar levels, elevated blood
pressure, enlarged waist circumference, elevated triglyceride levels, and low HDL
cholesterol (Alberti et al., 2009; Wilcox, 2005). I discuss the metabolic syndrome theory
further in Chapter 2.
The positivistic theoretical approach that uses deductive reasoning was also a
framework for this study (Institute of Medicine [IOM], 2003a, p. 2). I discuss this topic
further in Chapter 2. The deductive reasoning focuses on the relationships between
variables such as the environment and the individuals’ health (Liehr & Smith, 1999).
These approaches promote the identification of challenges encountered in the treatment
process and encourage the development of programs that promote positive behavioral
changes that lead to healthy lifestyles.
Nature of the Study
This study was a quantitative, cross-sectional study. Quantitative studies focus on
establishing relationships between the independent and dependent variables (Creswell,
2009). This study is in line with the focus of quantitative studies to determine the
prevalence of hypertension, obesity, diabetes as metabolic syndrome and examined the
association among HAART regimen and hypertension; HAART regimen and obesity;
and HAART regimen and diabetes among HIV-positive patients 18 years and older in
Umuahia, southeastern Nigeria. This study used the observational study design and crosssectional data collection method. This study was a retrospective study of prospectively
collected data of HIV-positive patients 18 years and older managed for HIV infection
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between January 2009 and January 2013 at the Federal Medical Centre, Umuahia, Abia
State, Nigeria. According to Hess (2004), in retrospective studies, the baseline state,
intervention, and outcome are collected from existing data collected for purposes other
than the study. I used the observational study design because it is a quantitative option
that enables the comparison of pre-existing groups (HAART and non-HAART)
retrospectively without doing any intervention (Al Amoor, 2013). I chose a crosssectional design because the study determined the prevalence of hypertension, obesity,
and diabetes as metabolic syndrome components, and I collected samples from the
population at the one-time point only (Crosby, Diclemente, & Salazar, 2006). The
secondary data of patients’ treatment record included information at baseline before
antiretroviral therapy (ART) initiation, previous laboratory results, ART history, clinical
manifestations of metabolic syndrome, and sociodemographic characteristics. The
methods used for the study was adapted from the studies of Berhane et al. (2012); Denue,
Muazu, Gashau, Mbo, & Ajayi (2012); Diouf, Cournil, BaFall, Ngom-Gueye, EymardDuvernay et al. (2012); Muhammad et al. (2013); and Tadewos, Addis, Ambachew, &
Banerjee, (2012). I discuss the methods in detail in Chapter 3.
I divided my target population into four strata (those cases not on HAART, those
on HAART for 6 months, 12 months, and those on HAART for >12 months) from where
I collected my samples. I used the pre or non-HAART cases as controls. The
proportionate stratified random sampling was employed. This stratified technique
required dividing the population into subgroups or strata, and then the final subjects
selected consecutively from the different strata (Explorable.com, n.d.).
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Using the G*Power 3.1.9.2 statistical power analysis software, the z test, logistic
regression statistical test, binomial distribution, a power of 0.80, α of 0.05, and effect size
(as odds ratio) of 2.333333, I calculated the sample size to be 186. I made up the sample
size to 192 and then allocated 48 subjects to each stratum (Berhane et al., 2012). I chose
the effect size as odds ratio because the dependent variable in the study is binary (Wilson,
2015).
I used Statistical Package for Social Sciences (SPSS) version 23 to analyze my
data, and I used descriptive statistics to determine the prevalence of metabolic syndrome
components. Furthermore, I used multiple logistic regressions to examine the association
between HAART regimen and the metabolic syndrome components. I used multiple
logistic regressions because according to Szklo and Nieto (2014), multiple logistic
regression is used to examine relationships between the predictor variables, and the
outcome (dependent) variables while allowing the control for possible confounders.
Multiple logistic regressions are also used when the dependent or outcome variable is
binary (Szklo & Nieto, 2014). In this study, the outcome of interests is presence or
absence of hypertension; presence or absence of obesity; presence or absence of diabetes
mellitus.
The metabolic syndrome components (hypertension and diabetes) were defined
according to the guidelines of the National Cholesterol Education Program (NCEP) ATP
III (Grundy, et al., 2005), whereas obesity was defined according to WHO (2015) criteria.
The following criteria were used: (a) elevated blood pressure of ≥130/≥85 mm Hg or
treatment for hypertensive; (b) BMI ≥25kg/m2 is overweight; BMI ≥30kg/m2 are obese;
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(c) fasting blood glucose >100 mg/dL, or antidiabetic treatment. The dependent variables
(hypertension, obesity, diabetes) were categorized as presence = yes or absence = no. The
independent variables were categorized as pre-HAART, HAART regimen at 6 months,
HAART regimen at 12 months, and HAART regimen >12 months. The measures
included fasting blood glucose test, blood pressure measurement, and weight and height
measurements. I included age, gender, and CD4+ cell count as confounding variables.
Statistical significance of odds of those with metabolic syndrome components and
those without a component were determined by p < .05 and 95% CIs. Rejection of the
null hypotheses supported statistical significance for hypertension, obesity, and diabetes.
I provided details of the methods in chapter three.
Definitions
I used the following definitions in this study:
Highly active antiretroviral therapy (HAART): A cocktail of a minimum of three
classes of antiretroviral drugs─PIs, nonnucleoside reverse transcriptase inhibitors
(NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs).
Metabolic syndrome (MetS): MetS is a combination of any three of the five
metabolic syndrome components (hyperglycemia, hypertension, hypertriglyceridemia,
low HDL cholesterol, and central obesity) (Grundy et al., 2005).
Hyperglycemia: Hyperglycemia as defined by the ATP III guidelines is elevated
blood glucose level above 100 mg/dL (NCEP, 2002).
Hypertension: Hypertension as defined by ATP III guidelines is elevated blood
pressure greater or equal to 130/85 (NCEP, 2002).
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Obesity: Obesity was defined as BMI ≥ 30 kg/m2 (WHO, 2015).
Assumptions
The first assumption in this study was that data is an accurate representation of the
HIV population in Umuahia metropolis because of the location of the study center, and
the population of clientele that patronizes the center (Federal Medical Centre, Umuahia).
The hospital is a tertiary hospital that has an antiretroviral therapy clinic (ART clinic) that
serves as a referral center for several communities, from where patients requiring ART
care are referred (FMC Umuahia, 2014). The second assumption was that data on
hypertension, obesity, and diabetes would be available in the patients’ treatment charts in
the medical records (FMC Umuahia, 2014). Laboratory test results were abstracted
directly from the medical records. A third assumption was that blood pressure, weight,
height, and blood glucose level tests were measured at baseline and thereafter. A fourth
assumption was that blood glucose tests results were documented with the fasting test
status according to the WHO recommendation (WHO, 2006).
Scope and Delimitations
This study was limited to and dependent on previously collected data from
patients’ treatment records to establish the prevalence of hypertension, obesity, and
hyperglycemia; and the relationship between HAART and diabetes, HAART and obesity,
and HAART and diabetes. In addition, the study was dependent on information
documented during the examination at baseline. This study was further limited to the
frequency of laboratory investigations in line with the frequencies of patients’ visits to
the clinic. With regard the dependent variables (hypertension, obesity, and diabetes); the
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study was limited to the definition by ATP III and WHO guidelines, as well as the
antiretroviral drug combination used in the facility. The study was also limited to markers
of metabolic syndrome components such as hyperglycemia, and hypertension, as well as
the CD4 cell counts, weight measurements, and height measurements. Covariates were
limited to gender, age, and CD4+ cell count.
The study population included HIV-positive patients 18 years and older who
attended the ART clinic in FMC, Umuahia, southeast Nigeria between January 2009 and
December 2013. The outcome of this study may be generalizable to the infected
population in Nigeria. Muhammad et al. (2013) used the HAART regimens that are
mostly used in sub-Saharan Africa in their study. They reported that their cohort study
was representative of the participating community. Similarly, this cohort study will use
the same HAART regimen.
Limitations
The limitations that apply to retrospective cohort studies also apply to this study.
Also applicable are the limitations that apply to medical chart reviews (Hess, 2004; Wang
et al., 2010). These limitations include reliance on information provided by patients on
family history and accuracy of documented records of patients. These could lead to recall
bias. In addition, incomplete critical data such as laboratory test results could be a
limitation in this study (Hess, 2004); selection bias as a consequence of the relationship
between exposed and unexposed patients to the outcome of interest (Aschengrau &
Seage, 2008, p. 267). According to Aschengrau and Seage, in retrospective cohort
studies, selection bias occurs when the outcome of interest is related to the exposed and
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unexposed individuals. Other limitations would include difficulty in controlling
confounders and bias as a result of nonrandomization and blinding (Hess, 2004).
However, these limitations can be managed. To minimize loss of validity and loss of
reliability caused by selection bias, I used the same criteria for the selection of cases and
controls, and I managed bias due to nonrandomization by using a control group made up
of individuals with diseases (Aschengrau & Seage, 2008, p. 282).
Significance
This study is unique because it addressed an area of research that focuses on the
relationship between HAART and metabolic syndrome components, which has been
understudied in southeastern Nigeria. The burden would be enormous if HIV-infected
individuals come down with other chronic diseases such as hypertension, diabetes or
hyperlipidemia that are characteristics of metabolic syndrome, and risk factors for CVD
(Palios, Kadoglou, & Lampropoulos, 2012). In addition, having to treat the additional
chronic illnesses not only poses problems in the treatment process but can be an
enormous financial burden for the individual (CDC, 2013). Thus, the results obtained in
this study could provide insights into the factors that contribute to developing metabolic
syndrome in HIV-infected individuals, with a view of developing intervention programs
on lifestyle changes (diet and exercise) to prevent metabolic syndrome while on
antiretroviral drugs. These intervention programs could minimize the risk for
cardiovascular disease, reduce patients’ medical expenditures, and cost of health care
generally, thereby promoting positive social change by improving the quality of life of
these groups of individuals.
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Summary
The management of infected patients and reduction of HIV/AIDS epidemic in the
developing nations using HAART is not without a price (Denue et al., 2012). The price
includes metabolic abnormalities. These lead to certain risk factors for CVD (Paula et al.,
2013). Metabolic syndrome components (hypertension, obesity, diabetes, elevated
triglycerides ≥150 mg/dL, low HDL cholesterol <40 mg/dL in men, <50 mg/dL in
women) are increasingly becoming important factors in the treatment of HIV-positive
patients globally (Paula, Falcão, & Pacheco, 2013; Subbaraman, Chaguturu, Mayer,
Flanigan, & Kumarasamy, 2007). Wu et al. (2012) found in their study that a metabolic
syndrome was developed in about a quarter of HIV-infected patients on HAART.
However, there may be variations in the distribution of the adverse effects of metabolic
syndrome between developed and developing nations (Subbaraman et al., 2007). These
differences distribution are due to host genetic makeup (Subbaraman et al., 2007), diet,
physical inactivity, and obesity (Paula et al., 2013) as independent risk factors for
metabolic syndrome. Although there is the consensus that metabolic syndrome
components are modifiable and associated with HAART regimen and cardiovascular
disease, several studies showed that the relationship between HAART and metabolic
syndrome components differs in diverse populations and regimen (Razzouk & Muntner,
2009; Rosolova & Nussbaumerova, 2011; Wu et al., 2012). Identification of risk factors
could form the basis to develop and provide intervention programs for the target
population. Thus, this study examined the relationship between types of HAART regimen
and hypertension, types of HAART regimen and obesity, and types of HAART regimen
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and hyperglycemia. The study also examined the relationship among duration of HAART
regimen and hypertension, duration of HAART regimen and obesity, and duration of
HAART regimen and hyperglycemia among HIV-positive adults 18 years and older in
Umuahia, southeastern Nigeria. I conducted this study with a view of identifying the risk
of CVD in HIV-positive adults on HAART in this study area to inform preventive
interventions that could promote positive social change. The prevalence of hypertension,
obesity, and diabetes was also determined.
I review the literature that includes the framework that directed the study in
Chapter 2. I also discuss studies that demonstrate the prevalence of hypertension, obesity,
and diabetes among the HIV-positive population on HAART in Chapter 2. In addition, I
review recent literature that demonstrates the association among HAART, hypertension,
hyperglycemia, and obesity as metabolic syndrome components in Chapter 2.
Furthermore, I discuss in detail studies that used secondary data and I describe their
methods in Chapter 2.
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Chapter 2: Review of the Literature
HAART considerably increases the risk for MetS and CVD in HIV-infected
patients (Kiage et al., 2013; Tadewos et al., 2012). The prevalence of metabolic disorders
is on the increase (Berhane et al., 2012; Muhammad et al., 2013). The increasing
prevalence has made management of HIV infection with HAART a cause for concern
globally (Paula et al., 2013; Subbaraman et al., 2007). Risk factors for metabolic
syndrome components include HAART regimen, duration of HAART regimen, age, and
gender (Grinspoon, 2009). Other modifiable risk factors for metabolic syndrome
components include smoking status, physical inactivity, diet, and obesity (Paula, Falcao,
& Pacheco, 2013). Cross-sectional studies confirmed that metabolic syndrome
components are prevalent among HIV-positive patients on HAART in Nigeria
(Muhammad et al., 2013) and other developing nations (Berhane et al., 2012; Malangu,
2014; Tadewos et al., 2012). However, there has not been any study on the analysis of the
relationship between HAART and metabolic syndrome in this study population in
Umuahia metropolis to date.
The purpose of this study was to: (a) examine the relationship among types of
HAART regimen and hypertension, obesity, and diabetes mellitus among HIV-positive
patients 18 years; (b) examine the relationship between duration of HAART regimen and
hypertension, obesity, and hyperglycemia as components of metabolic syndrome among
HIV-positive patients 18 years; (c) determine the prevalence of hypertension, obesity,
and hyperglycemia as components of metabolic syndrome among HIV-positive patients
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18 years and older attending the clinic at the Federal Medical Centre, Umuahia southeast
Nigeria.
In this literature review, I present the hypothetical model approach that promotes
the approach to the practice of public health (Institute of Medicine [IOM], 2003). This
approach provides the foundation for the application of theories at the individual level
and the population level (IOM, 2003). In the hypothetical model, it is assumed that all
exposures and disease outcome are linked (IOM, 2003). In this chapter, I present the
metabolic syndrome theory that explains the relationship among HAART, hypertension,
obesity, and hyperglycemia, and the relationship among duration of HAART regimen,
hypertension, obesity, and diabetes mellitus (American Diabetes Association [ADA],
n.d.).
I review studies that demonstrate the prevalence of hypertension, obesity, and
diabetes mellitus as components of metabolic syndrome among the HIV-positive
population on HAART. Recent literature that demonstrates the association between
HAART, hypertension, obesity, and diabetes mellitus as components of metabolic
syndrome are discussed as well in this chapter. Details of studies that used secondary data
and that described their methods are also reviewed in this section. The dependent
variables are hypertension, obesity, and hyperglycemia (presence or absence of each of
the variables). The independent variables are HAART regimen and duration of HAART
regimen (HAART at 6 months, HAART at12 months, and HAART >12 months).
Confounding variables include age, gender, and CD4+ cell count. I also discuss the gaps
in knowledge and how this study proposes to address the gaps and improve the overall
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health of HIV-positive patients on HAART in this chapter. Finally, I summarize the
sections of Chapter 2 in the summary section.
Literature Search Strategy
Search strategies used for this literature review included peer-reviewed journal
articles retrieved from Google advanced search engine, published lectures, dissertations
retrieved from Walden University Library, and databases such as PubMed, MEDLINE,
and Cumulative Index to Nursing & Allied Health Literature (CINAHL). Key search
terms included prevalence, HAART, diabetes, metabolic syndrome, and HIV-infection.
The search terms were used individually as well as in combinations. Only peer-reviewed
articles from databases that returned abstracts of articles in the past 5 years with search
key terms were included. Using the previous 5 years range was to ensure relevant
reviews. However, articles from databases that returned abstracts beyond five years
related to theoretical framework and constructs were included. The search was further
narrowed down by adding the words Umuahia, Abia state Nigeria. Queries of peerreviewed articles 2009 and beyond that returned recent relevant studies related to the
prevalence of diabetes, hypertension, obesity, metabolic syndrome, HAART, and HIV
infection were included. Further scanning of article titles returned several other relevant
articles for full-text reviews with authors, references, and publications.
Theoretical Foundation and Conceptual Framework
The first step in identifying factors that affect health is by conducting
epidemiological studies which are prompted by observational phenomenon and events
(Kamanger, 2012). These events could be triggered by biological, chemical, or
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physiological factors found in the physical environment. As a result, observational
studies focus on exposures and disease occurrence by exploring the different associations
found among variables. The associations include the relationship between diseasecausing agents, host and the environment (epidemiology triangle) as regards infectious
diseases (Ferng, n.d., p 4). Conversely, as regards chronic diseases, the focus is on the
physiologic changes of the host that occur as a result of the relationship between host
behavior and the environmental factors (McKenna & Collins, 2010). A combination of
theories that include the “systems theory” and the metabolic syndrome theory were used
in this review.
The CDC’s “systems theory” has its focus on understanding the fundamental
interactions of all the different make-ups of the system (Ferng, n.d., p 5). The system is
said to be made up of the agent, host characteristics, and environmental factors
(epidemiology triangle) (Ferng, n.d., p 5). In this system, the agents are classified into
biological, chemical, and physical; while the factors that affect the susceptibility of the
individual to causative agents include gender, lifestyle, race, socioeconomic status, and
age (Ferng, n.d., p 5). Furthermore, the theory of chronic diseases in the population is
also supported by observational studies (IOM, 2003b). However, regarding chronic
diseases, this theory provides the foundation that chronic diseases evolve from exposures
to a combination of genetic, behavioral, and environmental factors (IOM, 2003b). The
rates and types of chronic diseases may differ across populations due to genetic and
behavioral characteristics peculiar to the different populations (IOM, 2003b). These
various features play significant roles in influencing the disease risk factors in
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populations, which in turn provoke series of events that leads to morbidity and mortality
if not prevented. Hence, public health focuses on interrupting the chain of events that
leads to morbidity and mortality through ecological epidemiology studies using exposure
data (IOM, 2003b).
In summary, the “systems theory” examines the different components or factors
that influence health at the population level (Ferng, n.d., p 5). Since individuals make up
populations, the same environmental and societal factors affect individual behavior.
Thus, social, economic status, age, ethnicity, geographic location, gender, and economic
policies influence individual health by shaping individual behavior (Kaplan, 1989).
Although there is knowledge on the theoretical concepts of individual health about
population health, there is the need to close the gap that exists in the understanding of
why there are variations in the rates of chronic disease (Kaplan, 1989). Researchers
conducted epidemiologic studies to compare and contrast risk factors that are associated
with chronic diseases in populations to fill this gap. Population level intervention
programs that target reduction of chronic diseases are then developed based on the
outcomes of the epidemiologic studies.
Metabolic Syndrome Theory
The metabolic syndrome theory is based on the clustering of metabolic
abnormalities that increase the risk of CVD (Alberti et al., 2009; Grundy, Brewer,
Cleeman, Smith, & Lenfant, 2004; Mente, Yusuf, Islam, McQueen, Tanomsup et al.,
2010). According to Reaven (1988), hypertension, dyslipidemia, and hyperglycemia are
among several risk factors that cluster together in most cases. Reaven observed that this
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type of clustering is a complex system composed of several individual risk factors for
CVD, and named it Syndrome X. Reaven however excluded central obesity as a
component of syndrome X. In contrast to Reaven’s observation of the clustering of
metabolic risk factors, other researchers used the term metabolic syndrome (Alberti et al.,
2009; Grundy et al., 2006; Mente et al., 2010). Reaven postulated that insulin resistance
underlies Syndrome X and then used the term “insulin resistance syndrome” (Reaven,
1988). After that, Reaven proposed that the clustering of metabolic syndrome
components: increased levels of triglyceride, low levels of high-density lipoproteins,
glucose intolerance, increased levels of low-density lipoproteins, and increased blood
pressure increased the risk of CVD. Epidemiological studies showed that metabolic
syndrome occurs in different ethnic groups (Stem, 1997; Zimmert, 1992).
Metabolic syndrome is characterized by elevated blood pressure (hypertension),
hyperglycemia (elevated blood sugar levels), obesity, and dyslipidemia (abnormal lipid
levels) (Alberti et al., 2009; Grundy et al., 2004; Grundy, 2006). In defining metabolic
syndrome, several criteria that included clinical outcomes, therapeutic interventions,
metabolic components, the risk for clinical outcomes, clinical criteria for diagnosis and
pathogenesis were considered (Grundy et al., 2004). According to the National
Cholesterol Education Program (NCEP) (2002), it was viewed that the main clinical
outcome of metabolic syndrome is the CVD and that several risk factors were observed in
persons that developed CVD (Grundy et al., 2004). The 1979 Framingham study showed
that hyperglycemia and hypertension increased the risk for CVD (Kannel & McGee,
1979). Thus, a conclusion drawn from the Framingham study was that there is a greater
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risk of developing adverse clinical conditions when multiple risk factors are involved
than when only a single risk factor is involved (Framingham risk equation) (Grundy et
al., 2004).
Abnormalities of adipose tissue, obesity, and insulin resistance are said to be
potential causes of metabolic syndrome (Villamar, Albuja, & Salas, 2011). Independent
factors such as molecules of hepatic origin, immunologic origin, as well as the vascular
origin are also said to mediate metabolic syndrome components (Villamar, Albuja, and
Salas, 2011). However, it is said that both genetic and acquired factors regulate each risk
factor for metabolic syndrome. According to Grundy et al. (2004), metabolism of
lipoprotein is strongly modulated by variations in the genes. These variations in genes
result in the dyslipidemia being expressed in response to obesity or insulin resistance. In
the same vein, blood sugar levels are regulated by the insulin-secretory capacity and
insulin sensitivity. Other independent contributory factors that mediate metabolic
syndrome components include hormonal changes, aging, and pro-inflammatory state
(Grundy et al., 2004).
Reaven (1988) observed the association between elevated blood pressure and
hyperinsulinemia. He also noted that there was an association between hypertension and
obesity that was frequent (Reaven, 1988). This frequent association according to Reaven
was attributed to fluid retention and increase in circulating catecholamine produced in
hyperinsulinemia, as a result of the over stimulation of the sympathetic nervous system.
On the other hand, Kaplan’s attention was on the relationship between DM2 and body fat
distribution (Kaplan, 1989). Kaplan attributed abdominal/central obesity or adiposity to
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the association between DM2, body fat distribution, hypertriglyceridemia, and
hypertension. Kaplan further argued that the incidences of DM2 and CVD are increased
by abdominal obesity (Kaplan, 1989). Furthermore, Wang, Goalstone, and Drazin (2004),
linked the limited ability of insulin to confer protection on blood vessels from forming
atherogenic plaque to the association between hypertension and insulin resistance.
According to Grundy et al. (2004), insulin resistance may lead to elevated blood pressure
through different mechanisms. Also, production of low-density lipoprotein triglycerides
is enhanced by hyperinsulinemia which subsequently increases triglycerides levels.
Definitions of Metabolic Syndrome
The WHO (1999) provided a working definition of metabolic syndrome as the
presence of insulin resistance identified by: DM2, impaired fasting glucose or impaired
glucose tolerance in addition to any 2 of the following: High blood pressure (≥140 mm
Hg systolic or ≥90 mm Hg diastolic) and/or antihypertensive medication, plasma
triglycerides ≥150 mg/dL (≥1.7 mmol/L), HDL cholesterol ≥35 mg/dL (0.9 mmol/L) in
men or ≥39 mg/dL (1.0 mmol/L) in women, BMI ≥30 kg/m2 and/or waist-hip ratio >0.9
in men, >0.85 in women, and microalbuminuria (Urinary albumin excretion rate) ≥20
µgm/minute (WHO, 1999). WHO defined type 2 diabetes mellitus as fasting glucose
>126 mg/dl (7.0 mmol/L) and a 2-hour oral glucose tolerance test (2-h OGTT) ≥200
mg/dl (11.1 mmol/L); impaired glucose tolerance (IGT) as normal fasting and a 2-hour
oral glucose tolerance test ≥140 mg/dL (7.8 mmol/L).
The International Diabetes Federation (IDF), 2006) defined metabolic syndrome
based on the presence of increased waist circumference (abdominal obesity) in addition
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to at least two of five of metabolic syndrome components. In defining abdominal obesity,
IDF took the different ethnic groups into account. The European men whose waist
circumferences are ≥94 cm (37 inches) and European women with waist circumferences
≥80 cm (31.5 inches) are considered as having abdominal or central obesity (IDF, 2006).
However, central obesity was defined differently as waist circumference ≥102 cm (40
inches) in European men and ≥88 cm (35 inches) in European women; ≥90 cm (35
inches) in Asian American men and ≥80 cm (32 inches) in Asian American women by
the American Heart Association (AHA) and the National Heart, Lung, and Blood
Institute (NHLBI) (American Heart Association, 2014). Similarly, Adult Treatment Panel
(ATP) III (National Cholesterol Education Program (NCEP) (2002) defined metabolic
syndrome as the presence of any three of the five components of metabolic syndrome
without attributing any preference to any of the metabolic syndrome components. These
observed differences in the definition of metabolic syndrome created challenges in the
evaluation of the association between DM2 and metabolic syndrome within and across
populations (IDF, 2006). However, the ATP III guidelines with ethnicity-specific values
of waist circumference were adopted by most organizations to harmonize the criteria for
defining metabolic syndrome (Alberti et al., 2009).
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Table 1
New International Diabetes Federation Definition of Metabolic Syndrome Components

Metabolic syndrome
components

Cut points

Elevated fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or treatment of
previously diagnosed type 2 diabetes

Elevated blood pressure

systolic BP ≥130 or diastolic BP ≥85 mm Hg
or treatment of previously diagnosed hypertension

Decreased HDL cholesterol

<40 mg/dL (1.03 mmol/L) in males
<50 mg/dL (1.29 mmol/L) in females
or specific treatment for the lipid abnormality

Elevated triglyceride

≥150 mg/dL (1.7 mmol/L) or treatment for abnormal
lipid level

BMI

≥30 kg/m2

Note. HDL= High density lipoprotein, BP= Blood pressure, FPG= Fasting plasma
glucose, BMI = Body mass index.

Source: Adapted from International Diabetes Federation (2006)
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Table 2
ATP III Definition of Metabolic Syndrome Components
Risk Factor

Waist circumference
central obesitya

Measurement

Men
Women

Elevated blood pressurea Systolic blood pressure
Diastolic blood pressure
Low HDL cholesterola

Cut Points

>102 cm (≥40 inches)
>88 cm (≥35 inches)

≥130 mm Hg
≥85 mm Hg

HDL cholesterol
Men
Women

< 40 mg/dl (<1.03 mmol/l)
< 50 mg/dl (<1.29 mmol/l)

Elevated triglyceridesa

Triglycerides

≥150 mg/dl (>1.7 mmol/l)

Elevated fasting glucose

Fasting glucose
Currentb
Formera

≥100 mg/dl (>5.6 mmol/l)
≥110 mg/dl (>6.1 mmol/l)

Note. ATP III = Third Adult Treatment Panel, cm = centimeters, mm Hg = millimeters
Mercury, mg/dl = milligrams per deciliter, HDL = high-density lipoprotein, mmol/l =
millimoles per liter. aATP III guidelines (National Cholesterol Education Program, 2002)
b
ATP III guidelines modified to meet American Diabetes Association guidelines
Source: (Alberti et al., 2009).
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Definitions of HAART
HAART is defined as the use of two nucleosides or nucleotide reverse
transcriptase inhibitor (NRTI/NRTI) in combination with a non-nucleoside reverse
transcriptase inhibitor (NNRTI), the use of two NRTIs and a protease inhibitor (PI) or the
use of three NRTIs (Department of Health and Human Services [DHHS], 2004).
Mechanisms of Action of HAART
Metabolic changes such as elevated blood pressure, dyslipidemia, and insulin
resistance, which are components of metabolic syndrome, frequently been associated
with individuals infected with HIV on HAART (Palios et al., 2012). These metabolic
changes have resulted in a rise in the incidence of cardiovascular disorders among HIVinfected patients (Palios et al., 2012). According to Friis-Moller, Sabin, and Weber
(2003), the use of HAART in HIV-infected patients has increased the risk of myocardial
infarction by 26%.
The adverse effect of HAART on the arterial wall is said to be the underlying
mechanism behind myocardial infarction in HIV-infected individuals (Hsue, Hunt, &
Wu, 2009). However, other reports have implicated HIV infection through chronic
progressive inflammation, immunodeficiency, and endothelial cell dysfunction in the
development of atherosclerosis (Francisci, Giannini, & Baldelli, 2009; Hsue, Hunt, &
Schnell, 2009). It is, therefore, important to understand the underlying mechanisms of the
HAART-induced metabolic syndrome to enable the designing of effective interventions
to control cardiovascular diseases in this population.
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The liver centrally regulates lipid homeostasis. It is also the first organ that
ingested medicines including HAART come into contact (Zha, Studer, Zha, Hylemon,
Pandak et al., 2011). The ApoE endocytosis pathway converts lipids into chylomicrons in
the intestines, and finally ends up in the liver (Zha et al., 2011). Triglycerides (TGs) and
cholesterol are packaged in the liver into very low-density lipoproteins (VLDL) for
onward transport to peripheral tissues (Zha et al., 2011). Following lipase hydrolysis,
VLDLs and TGs are then taken up by adipose tissue and muscle. The lipoproteins that are
left known as intermediate density lipoproteins (IDL) are either converted to low-density
lipoproteins by lipases or endocytosis by cells. Lipids and cholesterols are sent back to
the liver by peripheral tissues to prevent overloading of LDL and signaling the liver to
stop further production of VLDLs, proteins. However, this pathway is said to be affected
by HAART (Zha et al., 2011).
The activation of the inhibition of sterol regulatory element-binding protein-1
(SREBP-1) in the liver, the protease-mediated breakdown of Apo lipoprotein-B, the
formation of very low-density lipoproteins, and lipase activity reduction are the potential
mechanisms underlying protease inhibitor (PI) associated dyslipidemia (Liang et al,
2001; Ranganathan & Kern, 2002). One of the side effects of HAART is insulin
resistance (Palios et al., 2012). According to Haugaard, Andersen, and Storgaard (2004),
PIs affect insulin sensitivity through the IRS-1 phosphorylation and glucose uptake from
adipocytes. Insulin signaling is mediated by the protein Akt (Zha et al., 2011). But the
insulin signaling action is inhibited by PIs which induce cellular insulin resistance.
Furthermore, Lee, Rao, and Grunfeld (2005) found a decrease in peripheral glucose
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uptake with PIs use. In the same vein, lipodystrophy causes impairment of insulin
feedback on B-cells, resulting in the dysfunction of B-cell. Thus, increase in visceral fat
and reduction in subcutaneous fat independently contribute to hyperinsulinemia and
insulin resistance in HIV-infected patients on HAART (Palios et al., 2012). Lipolysis
caused by antiretroviral drugs is also another way through which insulin resistance is
developed in HIV-infected patients on HAART (Grinspoon, 2003).
Application of Metabolic Syndrome Theory (MST)
The application of metabolic syndrome is very apparent in several
epidemiological studies (Beltrán-Sánchez et al., 2013; Berhane et al., 2012; Dimodi et al.,
2014; Ervin, 2009; Feleke, Fekade, & Mezegebu, 2012; Mhlabi, 2011; Villamar et al.,
2011; Wu et al., 2012). Metabolic syndrome has been applied to studies that examined
relationships between HAART and hypertension, obesity, diabetes.
This study focuses on the relationship between HAART and Metabolic syndrome
components (hypertension, obesity, diabetes). HAART causes malfunctioning of the
metabolic system (Muhammad et al., 2013). HAART leads to insulin resistance and
subsequently DM2 (Abebe, Kind, Belay, Gebreegziabxier, Challa et al., 2014). HAART
also leads to abnormalities of adipose tissues that result in obesity (Villamar et al., 2011).
Thus, adapting the MST will provide a good understanding of the relationship between
HAART and hypertension, obesity, diabetes.
Prevalence of Metabolic Syndrome Components
The epidemiological construct of metabolic syndrome components in individuals
living with HIV is associated with varying permutations of risk factors that present with
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unique treatment strategies and clinical implications (Ferrannini, 2007). To assess the
prevalence of metabolic syndrome and its components in populations, researchers apply
the appropriate study design and methods such as cross-sectional study design used in
this study. Cross-sectional studies according to (Crosby, Diclemente & Salazar, 2006) are
used to determine the prevalence of disease within a population at a one-time point only.
Researchers have raised concern over increased rates of metabolic syndrome and CVD in
HIV-infected population, thereby making metabolic syndrome a major public issue
(Biron, Bobin-Dubigeon, Volteau, Piroth, Perre et al., 2012; Ervin, 2009; Feleke et al.,
2012). Researchers reported the prevalence of metabolic syndrome components among
HIV-positive patients, and the relationship to HAART in several population-based crosssectional studies (Beltrán-Sánchez et al., 2013; Berhane et al., 2012; Diouf et al., 2012;
Feleke et al., 2012; Sachithananthan, Loha, & Gose 2012; Wu et al., 2012).
In Ethiopia, Sachithananthanet al. (2012) conducted a retrospective study and
examined the prevalence of diabetes Mellitus, hypertension, and lipodystrophy in HIV
patients receiving HAART in Sodo Government hospital in southern Ethiopia.
Sachithananthan and colleagues recruited one hundred and seventy-six subjects from
patients’ electronic database and analyzed data using descriptive statistics, Chi-square,
bivariate analysis, and multivariate logistic regressions. They recorded 8% (95% CI, 4.1–
11.9) prevalence of diabetes mellitus and 15.9% (95% CI, 10.5–21.3) hypertension. They,
however, found that the prevalence of hypertension (p = .007, COR: 5.73; 95% CI, 1.46–
22.58) in those with Lipohypertrophy was significantly higher (Sachithananthanet al.,
2012).
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In a similar cross-sectional study in Senegal, Diouf et al. (2012) examined the
prevalence of diabetes and hypertension, and the relationship between diabetes,
hypertension and antiretroviral treatment among HIV-positive patients. The authors
found that 28.1% of the 242 subjects had hypertension while 14.5% had diabetes. Using
multivariate logistic regressions, they also concluded that there was an association
between diabetes and long duration of ART (≥119 months), elevated cholesterol levels,
increased BMI, and older age. They, however, found that high triglycerides levels,
increased BMI, and older age were associated with increased risk of hypertension.
In Albania, Kolpepaj, Shkurti, Nake, Harxhi, Kolici et al. (2015) conducted a
study that investigated the metabolic problems associated with HIV treatment; focusing
on HAART –linked lipodystrophy and central obesity. The authors used multivariate
analysis to examine the associations and found that alteration of adipocytes, amplified
metabolic action in different adipose tissues, and imperfect lipogenesis, resulted to
HAART-linked lipodystrophy.
Prevalence of Metabolic Syndrome Components in Developing Countries
According to Gaziano, Bitton, Anand, Abrahams-Gessel and Murphy (2010),
there is an increase in the number of persons with metabolic syndrome components in
developing countries in the past couple of decades. Gaziano et al.; Gersh, Sliwa, Mayosi,
and Yusuf (2010); Mohan & Deepa (2006) observed the increase in the rates of morbidity
and mortality caused by CVD. The prevalence of metabolic syndrome in developing
countries as published by various studies ranged from 30.7% in Cameroon (Dimodi et al.,
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2014), 15% in China, 19% in Malaysia 20% in Indian using the ATP III definition of
metabolic syndrome (Mohan & Deepa, 2006).
In Cameroon, Dimodi et al. (2014) examined the prevalence of metabolic
syndrome and its individual components among HIV-positive patients in a prospective
cross-sectional study. The study was conducted with 492 infected patients 20 years and
older on antiretroviral therapy. Findings of the study showed 32.8% and 30% prevalence
of metabolic syndrome using the IDF and ATP III criteria respectively (p = .0001). They
also found the prevalence of metabolic syndrome to be 36% and 23.4% in patients
receiving HAART and HAART-naive patients (p = .0001) respectively (Dimodi et al.,
2014). The prevalence of the individual components was: abdominal obesity (40.5%;
26.9% (IDF and ATP III respectively); hypertriglyceridemia (55.5%), low HDL
cholesterol (42.5%), systolic hypertension (38.2%) diastolic hypertension (28.5%), and
hyperglycemia (31.2%; 1.3% p = .0001) (Dimodi et al., 2014). The study established that
prevalence of metabolic syndrome is dependent on the use of HAART, and the type of
HAART used.
Similar results were reported by Wu et al. (2012). Wu and colleagues reported
26.2% metabolic syndrome of a total of 877 HIV-positive patients on HAART in a crosssectional study conducted in a hospital in Taiwan. Wu and colleagues also reported an
association between prolonged exposure to HAART, PIs, NRTIs, and MetS (OR, 1.78;
95% CI, 1.03–3.07); (OR, 1.96; 95% CI, 1.13–3.42), and (OR, 1.91; 95% CI 1.11–3.30)
respectively (Wu et al., 2012).
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Prevalence of Metabolic Syndrome Components in Developed Countries
The prevalence of metabolic syndrome in developed countries is similar to that in
developing countries as observed by several researchers (Beltrán-Sánchez et al., 2013;
Ervin, 2009; Hansen et al. 2009; Lauda, Mariath, & Grillo, 2011). Ervin (2009) studied
the NHANES data from 2003 to 2006 that examined U.S adults 20 years and older as
participants. Ervin reported metabolic syndrome prevalence of 34%, and that metabolic
syndrome increased with age but differed by ethnicity. Ervin concluded that metabolic
syndrome varied by population (Ervin, 2009). Hansen et al., in a similar study reported a
metabolic syndrome prevalence of 27% in a retrospective HIV cohort study in Denmark.
In the same vein, Lauda et al. (2011) reported a metabolic syndrome prevalence of 20.9%
of which 18.5% were male, and 23.5% were female in a cohort of 249 HIV-infected
individuals 18 and older in Brazil. These studies all point to the increasing burden of
metabolic syndrome prevalence among the HIV-positive population, and that prevalence
cut across race/ethnicity and region both in the developing and developed nations.
When compared with countries in the developed world, the extent and degree of
adverse drug reactions related to HAART in developing countries have made the process
of dealing with HAART toxicity pivotal in the care and management of HIV
(Kumarasamy, VenKatesh, Cecelia, DeValeenal, Lai et al., 2008; Mills, Cooper, Seely &
Kanfe, 2005). Though Wu et al. (2012); Berhane et al. (2012) reported an association
between prolonged exposure to HAART and metabolic syndrome in Taiwan and Ethiopia
respectively, Hansen et al. (2009) on the other hand, reported no association between the
presence of metabolic syndrome and HAART duration in Denmark.

42
The severity of adverse effects could be related to the high prevalence of other
underlying disease conditions such as tuberculosis, malnutrition, anemia, and the
concomitant use of herbal medications with some individuals presenting with advanced
HIV disease at their initial hospital visit in developing countries (Mills, Cooper, Seely, &
Kanfe, 2005).
Effects of HAART on Blood Pressure
There is growing evidences that HIV-infected patients on HAART are at greater
risk of heart disease and stroke as a result of elevated blood pressure (Arruda Junior,
Lacerda, Moura, Albuquerque, Filho et al., 2010; Denue et al., 2012; Palacios et al.,
2006). Blood pressure according to NHLBI (2011a) is the force the heart exerts to pump
blood into the vascular system of the body. The heart is said to require more force to
pump blood efficiently in the system when there is resistance in the vascular system
(NHLBI, 2011a).
Investigations in Maiduguri, Nigeria affirmed the high prevalence (31.7%) of
hypertension among HIV-positive patients on HAART (Denue, et al., 2012). Denue and
colleagues examined the impact of HAART on blood pressure after two years of
commencement of HAART in a cohort of 227 patients. They used χ2 test or Fisher’s
exact test to analyze categorical variables and used the paired Student’s t-test to compare
baseline data with data 2 years after commencement of HAART. The result showed a rise
in blood pressure with time 3.47±15.21 vs. -0.71±16.28 (p = .08), 1.81±10.12 vs.
1.0±11.39 (p = .625) and 1.67±14.14 vs. 1.71±12.08 (p = .982). The authors thus
suggested periodic measurement of blood pressure and treatment where necessary of
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HIV-positive patients on HAART. Prevalence of hypertension with longer duration of
antiretroviral use was also reported by Arruda Junior et al. (2010) in a study in Brazil.
They also reported 25.6% hypertension prevalence, 14% pre-hypertension, and 40.5%
normotension (controls) in the participants, and concluded that there is a need for
measures to control factors such as unhealthy diet and excessive weight gain (Arruda
Junior et al., 2010). Palacios et al. (2006), in a prospective study of 95 HIV-infected
patients placed on HAART regimen reported 26% prevalence of hypertension. They
recommended periodic measuring and treatment where necessary of HIV-infected
patients on HAART.
Effects of HAART on Body Fat Distribution
Despite the benefits of HAART in reducing HIV levels in infected patients,
exposure to HAART is said to affect body fat distribution in HIV-infected patients, and
also increases the risk of CVD (Brown et al., 2009). The body store fat underneath the
(subcutaneous fat), and in the viscera (Reaven, 2011). The subcutaneous fat provides
insulation for the body, while the visceral fat provides a source of quick energy (Reaven,
2011). Abdominal adiposity (central obesity) is said to be associated with excessive
accumulation of visceral fat and also associated with the metabolic syndrome (Reaven,
2011). WHO defined obesity based on the body mass index (BMI) (WHO, 2015). Obesity
was defined as BMI ≥30kg/m2, overweight as BMI ≥25kg/m2, BMI 19-24.9kg/m2 as the
normal range, and BMI <19kg/m2 as being underweight. BMI according to WHO (2015)
is the weight of an individual in kilograms divided by the square of the individuals’
height in meters (kg/m2).
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In Jimma, southwest Ethiopia, Berhane et al. (2012) evaluated the prevalence of
lipodystrophy (fat metabolism disorder) and metabolic syndrome among HIV-positive
individuals on HAART. They reported lipodystrophy prevalence of 12.1% in a sample of
313 HIV patients 18 years and older. The study also revealed that taking the antiretroviral
therapy for 12 months and more was associated with metabolic syndrome male (AOR =
4.2; 95% CI = 1.24, 14.23) and female (AOR = 2.30; 95% CI = 1.0, 5.27). Berhane and
colleagues also found that taking the antiretroviral therapy for the longer duration of 12
months and more was independently associated with HIV-lipodystrophy (AOR = 3.59;
95% CI = 1.03, 12.54) (Berhane et al., 2012).
Sharma, Bynum, Schneider, Cox, Tien et al. (2014) followed 1177 HIV-positive
women in a prospective study for 15 years to examine changes in BMI after being
initiated on HAART regimen. The authors used the multivariate mixed-effects ordinal
logistic regression to estimate the degree of association of exposure with post-HAART
BMI. Sharma and colleagues reported that 39% of the women had normal BMI before the
commencement of HAART, but 40% of them became overweight, while 47% became
obese, and 27% morbidly obese at some point. This point to the hypothesis that duration
of HAART increases the odds of obesity
Effects of HAART on Glucose Metabolism
Glucose is a source of energy to body tissues, and a major factor in metabolism
(Merriam-Webster, 2015). It is transported into tissue cells by insulin (Merriam-Webster,
2015). Insulin also regulates the amount of glucose that circulates in the body (Schneider,
2014). In situations when there is insulin resistance, insulin is unable to control the
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amount of circulatory glucose, thereby resulting in elevated glucose in the blood stream
resulting in diabetes mellitus (Schneider, 2014). Thus, elevated blood glucose is a marker
for insulin resistance. Insulin resistance according to Bastard et al. (2006) determines the
production of excess adipokine leading to dysfunction of the endothelia. The endothelial
dysfunction leads to metabolic syndrome and diabetes mellitus with a progression of
endothelial damage (Bastard et al., 2006). Thus, the progression of endothelial damage,
as well as thrombosis and inflammation of the endothelia results in the production of
atherosclerotic plaques in the wall of the vessels (Bastard et al., 2006).
Insulin resistance and increased rate of diabetes mellitus have been associated
with HAART (Abebe et al., 2014; Brown, et al., 2005; Chukwuanukwu, Manafa, Ugwu,
Onyenekwe, Oluboyo et al., 2013). In Nigeria, Chukwuanukwu et al. determined the
prevalence of DM in HIV-infected patients on HAART using a sample of 150 patients.
The patients were grouped into two groups of 50 patients each according to the drug
regimen; first line drugs (lamivudine, nevirapine, combivir, combipack, and efavirenz );
second line drugs (truvada and aluvida) and a third control group of 50 patients not on
HAART. The authors reported a prevalence of 6% diabetes mellitus with the second line
regimen, 0% prevalence with the first line regimen, and 10% prevalence of impaired
glucose intolerance (Chukwuanukwu et al., 2013). Similar results were reported by
Abebe et al. (2014) in Addis Ababa Ethiopia, where they examined the association
between antiretroviral treatment and hyperglycemia and dyslipidemia among 126 HIVinfected patients on HAART in the Burayu health center. The results showed that
hyperglycemia was 7.9% prevalent in the HAART initiated group and 5.6% prevalent in
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the non-HAART group. However, they recorded no significant difference between
HAART initiated and the HAART-naive group (p = .45).
Similarly, Butt, McGinnis, Rodriguez-Barradas, Crystal, Simberkoff et al. (2009)
reported 21.4% (p < .0001) prevalence of diabetes in HIV-infected patients on HAART
compared to 14.9% HIV-infected patients at baseline in the veterans aging cohort study
(VACS) prospective study of 3,327 HIV-infected patients and 3,240 HIV-uninfected
subjects (controls) in the U.S. They also reported that HIV was associated with the use of
NRTI, NNRTI therapy and that NRTI; NNRTI therapy increased the risk for diabetes in
HIV-infected individuals (Butt et al., 2009). These reports all support the hypothesis that
HAART increases the odds of diabetes mellitus (hyperglycemia).
Metabolic Syndrome and Cardiovascular Disease
The risk for CVD is substantially increased by HIV infection and HAART
(Kingsley et al., 2008; Triant et al., 2007). Cardio-metabolic outcomes in patients living
with HIV infections and combination antiretroviral therapy have being established by
several studies (Kingsley, Cuervo-Rojasc, Muñozc, Palellad, Post, Budoff, Kingsley,
Palellad, Witt et al., 2008; Post, Budoff, Kingsley, Palella, Witt et al., 2014; Triant, Lee,
Hadigan, & Grinspoon, 2007). The independent association of the aforementioned cannot
be overemphasized as studies have established the association of HAART with insulin
resistance, elevated serum triglycerides (TG), low-density total and lipoprotein
cholesterol (TC & LDL-c) (Fontas, van Leth, Sabin, Friis-Moller, Rickenbach et al.,
2004; Jones, Sawleshwarkar, Michailidis, Jackson, Mandalia et al., 2005; Passalaris,
Sepkowitz & Glesby, 2000). Similarly, increases in the level of LDL-C has been reported
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to be associated with the thickening of the arterial walls (atherosclerosis), CVD, coronary
heart disease, and coronary artery disease resulting in myocardial infarction and stroke
(Roger, 2011).
The relationship between metabolic syndrome and CVD has been demonstrated
by several researchers in Nigeria (Muhammad et al., 2013), Zambia (Kiage et al., 2013),
and Addis Ababa (Feleke et al., 2012). Muhammad et al. evaluated the cardiovascular
risks among patients on HAART in a cross-sectional study of HIV patients placed on
HAART for six months and above, and HAART naïve group in Aminu Kano Teaching
Hospital, Nigeria. The researchers found that there was an increased proportion of
cardiovascular risk in individuals placed on HAART. The incidence of hypertension in
patients exposed to HAART was approximately eight times higher when compared to the
non-exposed, 17% and 2% respectively (p < .001) (Muhammad et al., 2013). The study
established significant correlations in cardiovascular risk factors such as metabolic
syndrome, obesity and hypercholesterolemia in patients treated with HAART. Kiage et
al. on the other hand conducted a retrospective study of 210 HIV-positive patients 16.5 60 years old using the dataset from the diet, genetic polymorphisms in lipid-metabolizing
enzyme genes, and antiretroviral therapy-related dyslipidaemia (DGPLEAD) in Lusaka,
Zambia from January to December 2007. The researchers found that there was an
association between cardiometabolic risk markers and combined anti-retroviral therapy
regimen; changes in cardiometabolic risk markers and duration of combined antiretroviral therapy regimen. Furthermore, Feleke et al. (2012) explored the risk factors and
prevalence of cardiovascular complications and chronic metabolic abnormalities in a
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cross-sectional study in Addis Ababa. The authors reported the prevalence of
hypertriglyceridemia as 15.2%, lipid density lipoprotein cholesterol as 54.2% and the
prevalence of hypercholesterolemia as 38.2%. They also reported that the prevalence of
hyperlipidemia was considerably high 56.9% (319) amongst study participants. Feleke et
al. further established a significant association in the development of
hypertriglyceridemia, lipohypertrophy and lipoatrophy in individuals exposed to HAART
for duration of at least a year or more and reiterated the importance of monitoring adverse
events in patients on HAART for metabolic abnormalities.
Summary
Metabolic syndrome is based on the premise that three or more of the five
components are present (NCEP, 2002). Metabolic syndrome is composed of a
combination of hypertension, obesity (central obesity), elevated blood sugar, and
dyslipidemia. In this study, I used hypertension, obesity, and hyperglycemia as metabolic
syndrome components. These components are risk factors for CVD. Although according
to Reaven (2011), metabolic syndrome is not a risk assessment tool, it explains the
relationships that exist between metabolic abnormalities and clinical outcomes.
Exposure of HIV-infected individuals to antiretroviral therapy predisposes them
to abnormal glucose metabolism and dyslipidemia, with low HDL cholesterol and
hypertriglyceridemia predominating in HIV-related metabolic syndrome (Fontas et al.,
2004). Non standardization of measurement while capturing clinical details of patients
give room for bias in the assessment of the prevalence of metabolic syndrome argued
Worm, Friis-Moller, Bruyand, Monforte, Rickenbach et al. (2010). For this reason, Worm
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et al. suggested that laboratory measurements be conducted two times consecutively and
that prevalence of metabolic syndrome should be based on this in cohort studies.
Assessing metabolic syndrome components in populations can go a long way in
determining the most prevalent component. This knowledge can help form the platform
on which effective prevention and intervention programs that adopt lifestyle changes to
reduce the prevalence of metabolic syndrome and CVD. I discuss in detail the methods
used in this study to determine the prevalence of hypertension, obesity, and
hyperglycemia; and examined the relationship among HAART, hypertension, obesity,
and hypertension as metabolic syndrome components in Chapter 3.
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Chapter 3: Research Method
This purpose of this retrospective quantitative study was to use medical
records/treatment charts to examine the relationships between types of HAART regimen
and hypertension, types of HAART regimen and obesity, and types of HAART regimen
and hyperglycemia. The study’s purpose was also, to examine the relationship between
duration of HAART regimen and hypertension, duration of HAART regimen and obesity,
and duration of HAART regimen and hyperglycemia. In addition, the purpose was to
determine the prevalence of hypertension, obesity, and hyperglycemia among HIVpositive patients 18 years and older attending the clinic at the Federal Medical Centre,
Umuahia, Nigeria.
I discuss the study design and methods in this chapter. I review the research
questions and I provide the rationale for using descriptive statistics to determine the
prevalence of hypertension, obesity, and hyperglycemia. In this chapter, I also explain
why I used multiple logistic regressions to examine the relationship among HAART
regimen, hypertension, obesity, and hyperglycemia.
Furthermore, I detail the study population, sample, and sample procedures, and I
describe the data collection methods and data analysis. In addition, I discuss the measures
I took to minimize bias and strengthen the internal and external validity in this section. I
also explain the procedures I followed to gain access to data and protect the study
participants.
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Research Design and Rationale
My aim in this study was to answer two major research questions and a series of
sub questions on the relationship among HAART regimen, duration of HAART regimen
and hypertension, obesity, and diabetes as metabolic syndrome components.
RQ1: Type of HAART Regimen
RQ1A. Is there an association between types of HAART regimen and elevated
blood pressure (hypertension) among HIV-positive patients 18 years and older in
Umuahia, southeast Nigeria?
RQ1B. Is there an association between types of HAART regimen and obesity
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria?
RQ1C. Is there an association between types of HAART regimen and elevated
blood glucose level (hyperglycemia) among HIV-positive patients 18 years and older in
Umuahia, southeast Nigeria?
RQ2: Duration of HAART Regimen
RQ2A. Is there an association between duration of HAART regimen and
hypertension among HIV-positive patients 18 years and older in Umuahia, southeast
Nigeria?
RQ2B. Is there an association between duration of HAART regimen and obesity
among HIV-positive patients 18 years and older in Umuahia, southeast Nigeria?
RQ2C. Is there an association between duration of HAART regimen and elevated
blood glucose level among HIV-positive patients 18 years and older in Umuahia,
southeast Nigeria?

52
The first question focuses on the relationship among HAART regimen and
hypertension, obesity, diabetes as metabolic syndrome components. I used the
quantitative research methods in this study. Quantitative methods use numerical data that
are analyzed statistically to explain phenomena that occur in the world (Burns & Grove,
2005, p. 23.) According to Burns and Grove, this method is used to describe variables
and determine cause-and-effect interactions between variables. Also, according to
Creswell (2009), quantitative studies focus on establishing relationships between the
independent and dependent variables. As in this study, HAART and duration of HAART
are the independent variables, while hypertension, obesity, and hyperglycemia are the
dependent variables). Also, to answer this question, the cross-sectional data that was
collected at one point in time was the basis for determining the prevalence of
hypertension, obesity, and hyperglycemia among HIV-positive patients in this study.
As indicated in Chapter 1 of this dissertation thesis, the quantitative option
enables the comparison of pre-existing groups (ART and non-ART) retrospectively
without doing any intervention (Al Amoor, 2013). According to Crosby, Diclemente and
Salazar (2006), cross-sectional studies that use data drawn from the population at a onetime point only are used for prevalence studies. Furthermore, to establish whether
HAART regimen increases the odds of high blood pressure, obesity, and hyperglycemia,
the presence of HAART regimen before the onset of these metabolic variables, were
observed. Likewise, the temporal association between the onset of high blood pressure,
obesity, hyperglycemia and HAART regimen were confirmed by comparing the
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prevalence of risk factors in the individuals who did and did not develop high blood
pressure, obesity, and hyperglycemia (Nicholols, & Moler, 2010).
The second question is whether there is an association among duration of HAART
regimen and high blood pressure, duration of HAART regimen and obesity, duration of
HAART regimen, and diabetes as components of metabolic syndrome in the study
population. Prevention programs can be strengthened if the focus is on reducing risk
factors that can bring about enormous health problems. As a result, knowing whether the
duration of HAART regimen increases the odds of hypertension, obesity, and
hyperglycemia is necessary. Thus, understanding the risk factors that predict these
metabolic syndrome components in HIV-positive patients in Umuahia will prevent or
delay development of metabolic syndrome components in the study population, as well as
enable population specific intervention programs to be brought closer to the community
(Howard, Rodriguez, Bennett, Harris, Hamman et al., 2002).
Relationships among HAART and high blood pressure, obesity, and
hyperglycemia were determined by the odds ratios and the respective p - values and 95%
CIs for each independent variable. Independent variables include HAART regimen and
duration of HAART regimen. The independent effects of each variable on these
metabolic syndrome components were analyzed using multiple logistic regression models
when other covariates were controlled. It was assumed that in multiple logistic regression
analysis, the logit (natural logarithm of the odds of the outcome) changes linearly with
multiple independent variables. Multiple logistic regressions also assume that the
outcome is a binomial distribution (Katz, 2006). The assumption for a binomial
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distribution was met in this study since the outcome was presence or absence of
hypertension; absence or absence of obesity; presence or absence of hyperglycemia.
Furthermore, to meet the second assumption of logit changes with multiple independent
variables, I divided continuous variables such as age into categorical groups to create
dichotomous variables. According to Katz, multiple covariates could be categorical or
continuous.
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Table 3
Study Variables
Variable type

Variable name

Potential response

Level of measurement

Dependent

Hypertension

Presence of hypertension = 1
Absence of hypertension = 0

Nominal

Dependent

Obesity

Presence of obesity = 1
Absence of obesity = 0

Nominal

Dependent

Diabetes

Presence of diabetes = 1
Absence of diabetes = 0

Nominal

Independent

HAART

Lam, stav, nvp = 1
Comb, nvp = 2
Comb, efv =3
Truv, efv = 4

Independent

Covariate

Duration of
HAART

Age

Pre HAART = 0
<6 months = 1
6–12 months = 2
>12 months = 3
18–29 =1
30–50 = 2
>50 = 3

Nominal

Nominal

Nominal

Covariate

Gender

Male =1
Female = 2

Nominal

Confounder

CD4+ cell
count

10–200 =1, 201–350 = 2
351–500 = 3, >500 = 4

Nominal

Note. HAART = Highly active antiretroviral therapy, Lam = Lamivudine, stav =
Stavudine, nvp = Nevirapine, comb = Combivir, efv = Efavirenz, Truv = Truvada.
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In this study, I used existing data from medical charts/ records of HIV-positive
individuals. I sought permission from the Health Research Ethics Committee of Federal
Medical Centre (FMC) Umuahia to access the medical records of the patients, to use data.
Medical record review according to Wickson-Griffiths, Kaasalainen, Ploeg, and McAiney
(2014) is a method used in collecting retrospective data, collecting data for research and
occupational therapy for performance analysis and quality assessment. The retrospective
methodology involves looking back in time into events (Panacek, 2007) as is the case in
this study where I will be looking into the medical records of my study population.
According to Hess (2004), in retrospective studies, the baseline state, intervention, and
outcome are collected from existing data collected for purposes other than the study.
Retrospective designs are useful when evaluating or assessing palliative and end -of-life
care, and when it’s hard or impossible to answer research questions prospectively (Hess,
2004).
Although the analysis of secondary data retrospectively eliminates the cost and
time of designing, funding, and implementing compared to conducting prospective cohort
studies; retrospective cohort studies do have some limitations or challenges (WicksonGriffiths et al., 2014). Some of the limitations of medical chart review in retrospective
studies include incomplete and inaccurate documentation, incomplete data, missing
charts, lack of binding to the study purpose, and inconsistency in the coding of chart
information (Wickson-Griffiths et al., 2014). These limitations according to WicksonGriffiths et al. may threaten the overall validity and reliability of this study.
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Population and Sampling
This study was conducted in the Federal Medical Centre (F.M.C) Umuahia,
southeast Nigeria. F.M.C Umuahia is a 327-bed tertiary hospital centrally located and
easily accessible. It is the only federal hospital in Abia state. The facility draws patients
and clientele predominantly from the southeast and south-south part of the country
(Nwadinma, 2013). The facility provides specialized services including HIV services for
both outpatients and inpatients. HIV services became available in Nigeria in the year
2004. However, HIV services in the facility commenced in the year 2006. The facility
runs an outpatient antiretroviral clinic.
In this facility-based retrospective study, the population source was HIV-infected
patients 18 years and older managed for HIV infection between January 2009 and
December 2013 in F.M.C., Umuahia. Because organized antiretroviral therapy unit
(ART) was established in January 2009, I used January 2009 as my study start date.
Umuahia is the capital of Abia state in south-eastern Nigeria and located at latitude 5,
5333 (531’59.988’’N) and longitude 7, 4833 (728’59.988’’E). It has a population of
359,230 people as of the last Nigerian census in 2006 and has Igbo as the traditional
language (The GPS Coordinates.net., n.d.). Umuahia is comprised of Umuahia North and
Umuahia South local government areas.
Sampling Procedures
The method for sampling was adapted from the study of Berhane et al. (2012).
The proportionate stratified random sampling techniques were employed. To achieve a
representative sample of a population, it is imperative to randomly select the samples
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(Frankfort-Nachmias & Nachmias, 2008). This stratified technique requires dividing the
population into subgroups or strata, and the final subjects are then selected sequentially
from the different strata (Explorable.com, n.d.). The stratified sampling technique helps
to highlight particular subgroups within the population. It is also employed in studies that
involve population with various attributes, as well as studies that observe existing
relationships (Explorable.com, n.d.) as is the case with this study. This technique was
chosen to evaluate the relationship between HAART regimen and development of high
blood pressure, obesity, hyperglycemia because of the variableness of the characteristics
of the target population. Each stratum was assigned the same sample size by the
proportionate stratified random sampling where the same sampling fraction is allocated to
each stratum (Explorable.com, n.d.).
Sampling Frame and Sample Size
I stratified my target population into four to accommodate all the categories of
HIV-positive individuals assessing treatment in the clinic (Pre-ART, those who took
HAART for six months, those who took HAART for twelve months, and those who
received HAART for twelve months and above) from where I collected the samples.
More so, eligible patients came for check-ups and refilled every three months, but did
their blood tests every six months. The pre- HAART cases were infected individuals who
were not eligible for antiretroviral therapy because their CD4+ cell count was above 350
cells/mL thresholds for eligibility and served as the control group. Based on the
assumptions that the outcome is binary and that there is a linear relationship between the
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predictors and the log of the outcome variables (Field, 2009), power analysis to
determine the sample size a priori was done.
I used the G*Power 3.1.9.2 statistical power analysis software for the power
analysis (Faul, Erdfelder, Buchner, & Lang, 2009). The power analysis was carried out to
determine the sample size with the following parameters of the G* Power software: The
Z test, logistic regression statistical test, binomial distribution, a power of 0.80, α of 0.05,
and effect size as odds ratio of 2.333333 (Figure 1). I used the odds ratio because the
outcome variable is binary (Karabi, 2012). I calculated the sample size to be 186, but the
sample size was rounded to 192 (48 subjects per stratum). Samples were then allocated to
the strata proportionately (Berhane et al., 2012).
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Figure 1. G-power analysis required sample size a priori.

Note. z tests - Logistic regression, tail(s) = two, odds ratio = 2.3333333
α = 0.05, power = 0.80, distribution = binomial, critical z = 1.9599640
total sample size = 186.
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Inclusion and Exclusion Criteria
The population for the study included medical records of adult HIV patients 18
years and older; those who adhered to taking HAART; those who had no abnormal blood
glucose, BMI, and elevated blood pressure at baseline. I excluded the medical records of
those below 18 years. The records of those who had elevated blood glucose, blood
pressure, and abnormal BMI at baseline were also excluded from the study. Also
excluded from the study were those whose records indicated pregnancy.
Data Collection Instrument and Measurement of Patients’ Samples
Information regarding age, sex, date of HAART initiation, type of HAART
received, duration of HAART regimen, weight, height, blood pressure, CD4+ cell count,
and fasting blood glucose were abstracted from the medical records of patients’ using an
abstraction form (Villamar et al., 2011). Blood pressure was measured using Reiseter
Exacta sphygmomanometer (Rudolf Reiseter, Jungingen, Germany). Fasting blood
glucose was measured using Selectra Junior chemistry auto analyser (ELITech Clinical
Systems, Netherlands). Weight and height were measured using GT 131-120 health scale
(Skyline Medical Equipment).
Data Access and Collection Process
I sought permission and approval of the study from the Institutional Review
Board (IRB) of Walden University following approval for data collection from medical
records of patients by the Health Research Ethics Committee (HREC) of F.M.C.
Umuahia. I removed every form of identifier that could link the patient to the study to
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protect patients’ rights to confidentiality in agreement with the Helsinki Declaration
(World Medical Association [WMA], 2008).
Data Validity
Data validity addresses the accuracy of the data (Creswell et al., 2009). According
to Creswell et al., the manner of data collection (internal factors) can interfere with the
validity of data. Data validity can be sectioned into internal and external validity (Cook &
Campbell, 1979, p. 5.). Internal validity borders on the soundness of the design and
analysis such as reliability of instrument and statistics, environment variables control, and
characteristics of participants while external validity borders on the question of
generalizability (Cook & Campbell, 1979, p. 5.). This includes the generalizability of the
effect of the study to populations, measurement variables, treatment variables, and
settings (Cook & Campbell, 1979, p. 5.).
Since confidence in a study can be achieved with only valid data (Creswell et al.,
2009), I ensured data validity and reduced external threats to validity by determining
whether data was stored electronically or by a paper chart. I also found out the type of
information that was recorded as suggested by Hall, Schroder, and Weaver (2002). I also
ensured data validity as stated by Engel, Henderson, Fergenbaum, and Colantonio (2009)
by using trained data entry clerks in the medical records department of the ART clinic to
abstract data from patients’ records. Furthermore, Engel et al. noted that the layout and
content of the abstraction form could enhance the reliability of the data abstraction form.
As a result, response fields on the abstraction form followed the order as it appeared in
the records. To further enhance data validity, I coded the variables numerically and
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aligned the response fields visually. I also justified to the right with no blank spaces to
avoid transcription and data entry errors as suggested by Banks (1998).
Statistical Power for Analysis
The margin of error also known as alpha (α) level or level of statistical
significance is important when conducting epidemiologic studies and it is set a priori
(Frankfort-Nachmias, & Nachmias, 2008). The alpha level is the level of error allowed to
reject a true hypothesis (Frankfort-Nachmias, & Nachmias, 2008). Statistical significance
is very vital in testing a statistical hypothesis. It plays a very crucial role in determining
when to reject or accept a null hypothesis (Meier, Brudney, & Bohte, 2011). Thus, a pvalue of 0.05 (probability) is equivalent to a chance of 1 in 20 of rejecting a true
hypothesis. By tradition, a p-value > .05 supports the null hypothesis and is not
statistically significant. On the other hand, a p-value < .05 is considered statistically
significant and does not support the null hypothesis (Frankfort-Nachmias, & Nachmias,
2008). Based on this, the level of significance was set at 0.05. Furthermore, to have
substantive and replicable results, the appropriate effect size must be applied as
Frankfort-Nachmias, & Nachmias posited. According to Kelley & Preacher (2012), the
quantitative measure of the strength of a phenomenon is the effect size. In addition, to
prevent type II error with logistic regression, I set the power (1-β) at 80% with 95%
Confidence interval (CI).
Statistical Analysis
Data that I extracted from the medical records were imputed manually into
Microsoft Excel. I then exported the data into SPSS version 23 for analyses after
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inspection and cleaning by excluding all missing data and used only records with
complete data for the analysis as stated by Frankfort-Nachmias, and Nachmias (2008). I
conducted descriptive statistics on my data and determined the prevalence of
hypertension, obesity, and hyperglycemia using frequency distribution of demographic,
laboratory, and clinical values. I also used the Chi-square test for independence (χ2) to
determine the association between categorical variables according to the methods of
Berhane et al. (2012). In addition, I used bivariate logistic analyses to identify predictors
of hypertension, obesity, and hyperglycemia. Thereafter, I used the multivariate logistic
regression analyses to analyse the independent variables that showed significant
associations (p < .05) with the bivariate analyses. Furthermore, I used the multiple
logistic regressions to estimate odds and odds ratio and controlled the effect of
confounding variables. Multiple logistic regressions enabled me to examine the
relationship between types of HAART regimen and high blood pressure, types of
HAART regimen and obesity, and types of HAART regimen and hyperglycemia (Denue
et al., 2012; Diouf et al., 2012). According to Kaneko et al. (2011); Wang et al. (2010),
high blood pressure, obesity, and diabetes vary by characteristics of the population, and
that gender, ethnicity, family history, differences in age, and smoking status contributes
to differences in metabolic syndrome. These factors can alter the effects of HAART
regimen on the dependent variables without being the direct cause of the outcome,
thereby confounding the effect size of the dependent variables (Kaneko et al., 2011).
Thus, preventing the effect of confounders informed the choice of multiple logistic
regressions. Multiple logistic regressions allow controlling for confounding variables
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(Szklo, & Nieto, 2014). According to Szklo and Nieto, multiple logistic regressions is
used to examine relationships between the predictor variables, and the outcome
(dependent) variable while allowing controlling for possible confounders. Multiple
logistic regression is also used when the dependent or outcome variable is binary (Szklo,
& Nieto, 2014). In this study, the outcome of interest is presence or absence of
hypertension, presence or absence of obesity, and presence or absence of diabetes. The
predictor variables (independent variables) are types of HAART regimen and duration of
HAART regimen. However, using the directed acyclic graph (DAG), only age, and
gender were included as covariates, CD4+ cell count was included as confounder. High
blood pressure, obesity, and hyperglycemia were analyzed independently by creating
dummy variables using the ATP III criteria (NCEP, 2002).
In my data analysis, I included age and gender as covariates because they are
patient variables, and they are related to the outcome variables only. However, I included
CD4+ cell count that represents the immune status of the patient as a confounder because
CD4+ cell count is related to both the exposure and the outcome (StraightHealthcare,
2015). According to StraightHealthcare, covariates are patient variables that could be
related or not related to the study outcome. But when the covariates are related to both
the exposure and outcome, they become confounders.
Study Variables
In this study, I derived the variables based on abstracted clinical information and
laboratory test results from the medical records of HIV-infected individuals. I coded the
outcome variables as presence of hypertension = 1, absence of hypertension = 0, presence
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of obesity = 1, absence of obesity = 0, presence of hyperglycemia = 1, absence of
hyperglycemia = 0. However, I coded the predictor variables (types of HAART regimen
and duration of HAART regimen) at five and four levels respectively: pre- HAART
(control) = 0, the use of lamivudine, stavudine, nevirapine = 1; the use of combivir,
nevirapine = 2; the use of combivir, efavirenz = 3; the use of truvada, efavirenz = 4;
baseline = 0, HAART regimen for 6 months = 1, 12months = 2, >12 months = 3.
Summary
In this study, I analyzed data from medical records of HIV patients. The aims of
this study are to: (a) examine the relationship among types of HAART regimen and
hypertension, obesity, and hyperglycemia among adult HIV positive patients 18 years
and older attending the clinic in F.M.C. Umuahia, Nigeria; (b) examine the relationship
among duration of HAART regimen, hypertension, obesity, and hyperglycemia among
adult HIV positive patients 18 years and older attending the clinic in F.M.C. Umuahia,
Nigeria; (c) determine the prevalence of hypertension, obesity, and hyperglycemia among
adult HIV positive patients 18 years and older attending the clinic in F.M.C. Umuahia,
Nigeria. The study was limited to: (a) data available in patients’ medical records; (b) data
that met the inclusion criteria of 18 years and older; (c) records that showed no evidence
of abnormal blood glucose level, BMI, and hypertension at baseline.
The effects of HAART on blood pressure, BMI, and blood sugar level were
analyzed using logistic regression analysis. I based statistical significance on p < .05 and
95% CIs. I took steps to ensure validity by minimizing bias, and also controlled
confounders. Following approval of this study by the Walden University IRB and
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approval to access patients’ medical records by HREC of F.M.C Umuahia, I then
collected data, cleaned, coded, and analyzed data. Thereafter, I analyzed data statistically
and present results in Chapter 4.

68
Chapter 4: Results
The purpose of this study was to analyse data from the treatment records of HIVpositive individuals accessing treatment in the ART clinic in Federal Medical Centre
(FMC), Umuahia quantitatively. In this study, I determined whether types of HAART
regimen and duration of HAART regimen significantly affect the odds of hypertension,
obesity, and hyperglycemia in HIV-positive individuals. The aim of this study was to
answer two research questions: (a) what is the relationship among types of HAART
regimen and hypertension, obesity, and hyperglycemia as metabolic syndrome
components in HIV-infected individuals? ; (b) What is the relationship among duration of
HAART regimen and hypertension, obesity, and hyperglycemia as metabolic syndrome
components in HIV-infected individuals? I also sought to determine the prevalence of
hypertension, obesity, and hyperglycemia among HIV-positive individuals receiving
treatment at the ART clinic in FMC Umuahia in this study.
In this chapter, I report the baseline descriptive and demographic characteristics
of the sample population first. Then, I report the results of univariate analyses that
justified the inclusion of covariates in the bivariate logistic model. Furthermore, I report
the results of the multivariate logistic model after determining their individual effect on
the outcome variables. In addition, I report the results of the multivariate logistic model
after including age, gender, and CD4+ cell count to control their effect. I also summarize,
tabulate, and report the findings of all statistical analysis about each hypothesis.
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Data Access and Acquisition and Characteristics of Study Population
Data Access and Acquisition
I sought for and obtained approval to access patients' treatment records from the
FMC HREC. The HREC approval number for the study is
(FMC/QEH/G.596/Vol.10/166. Data collection and analysis for this study could start
only when I got approval to carry out this study by Walden University’s IRB. The
Walden University’s IRB approval number for the study is 04-08-16-0322042. I
requested for Data from the medical records of all HIV-positive patients that accessed
treatment in the ART clinic in FMC Umuahia between January 2009 and December
2013. I then used only the records that met the inclusion criteria. I further derived
variables as listed under study variables in Chapter 3.
I coded all responses as described in Table 3 under study variables, and I limited
the responses for the covariates to age and gender, and limited confounders to CD4+ T
lymphocyte cell count. I limited the responses because other variables like family history
of hypertension, family history of diabetes, alcohol use and cigarette smoking status of
patients were not captured in the patients’ medical records. I also, used the term
hyperglycemia instead of type 2 diabetes mellitus because there was no sufficient
information such as Hb1C test, and information on the use of antidiabetic medication in
the records of patients.
Characteristics of Study Population
In this retrospective study, I defined the sample size as the total number (n= 192)
of treatment records of HIV-infected patients 18 years or older enrolled in the ART clinic
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between January 2009 and December 2013 that met the inclusion criteria. Meanwhile, for
the purpose of this study, I regarded the treatment records as participants, and I
dichotomized continuous data for hypertension, obesity, and hyperglycemia using the
ATP III criteria for hypertension and hyperglycemia and WHO criteria for obesity, as
described in Chapter 3 (Tables 3 and 2, respectively). I also categorized age, CD4+ cell
count, and WHO disease staging after obtaining their individual means. It is important to
note that all the participants in the HAART group adhered to their regimen. Frequencies
(number and percent) of the characteristics of the pre-HAART regimen control group and
HAART regimen group collected from January 2009 to December 2013 are presented in
Table 4.
Table 4 shows the characteristics of the pre-HAART and HAART group. The
sample size was 192 treatment records of HIV-positive patients 18 years and older. The
sample was stratified into four groups, based on the duration of HAART regimen as
follows: (a) pre-HAART (Control) = 48; (b) HAART group- 6months = 48; (c) HAART
group -12 months = 48; (d) HAART group- >12 months = 48. In some comparison, I
grouped three HAART groups as one single “HAART group” (Table 4). The preHAART group consisted of only patients who were yet to commence the HAART
regimen, whereas the HAART group consisted of HIV-positive patients on the HAART
regimen. Of the 48 participants in the pre-HAART control group, 18 (12.5%) were males,
whereas 30 (26.8%) were females. The age ranged between 18 years and 57 years. The
mean value for age was 35.3years, with the majority of the participants in the 18-29 and
40-50 years groups (Table 4). There was no participant on HAART regimen in the pre-
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HAART group. The immune statuses of patients as presented by CD4+ T lymphocyte
cell count range was 201 cells/mL─> 500 cells/mL. The WHO HIV disease staging of all
participants were below stage 3. Obesity was 12.5% prevalent with a mean BMI of 25.5.
There was no observed presence of hypertension (0.0%) and hyperglycemia (0.0%) in the
pre- HAART group (Table 4). Of the 144 participants in the HAART group, 59 (41.0%)
were males whereas 85(59.0%) were females. The age ranged between 23 years and 65
years, with a mean value of 38.7 years. The majority of the participants were in the age
group 30-39 years (39.6%). In the HAART group, there were 82 (28.5%) participants on
the lamivudine, stavudine and nevirapine regimen; 158 (54.9%) were on the combivir and
nevirapine regimen, while 24 (8.3%) each were on the combivir and efavirenz, truvada
and efavirenz regimen respectively. Obesity and hyperglycemia occurred in 16% and
31% of the participants respectively. Systolic hypertension was 73.4 %, with a mean
value of 142.2 mm Hg; diastolic hypertension was 26.6%, with a mean value of 93.4 mm
Hg. The average value for BMI was 23.4 kg/m2, whereas the average value for fasting
blood sugar was 85.9 mg/dL.
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Table 4
Characteristics of the Pre-HAART and HAART Group
Variable

Overall
Gender
Male
Female
Age group (years)
18-29
30-39
40-50
>50
Type of HAART
Lam,stav,nvp
Comb,nvp
Comb,efv
Truv,efv
CD4+ cell count
(cells/mL)
10-200
201-350
351-500
>500
WHO disease staging
<3
>2
Hypertension(mm Hg)
SBP (mm Hg)
DBP (mm Hg)
BMI (Kg/m2)
Obesity
FBS (mg/dL)
Hyperglycemia
Duration of HAART
Baseline
6 months
12months
>12 months

Pre-HAART
Frequency
N (%)
48 (25%)

Mean value

Mean value

-

HAART group
Frequency
N (%)
144 (75%)

18 (37.5)
30 (62.5)

-

59
85

(41.0)
(59.0)

-

15
14
15
0.4

(10.4)
(9.7)
(10.4)
(8.3)

35

21
57
54
12

(14.6)
(39.6)
(37.5)
(8.3)

38.7

0.0
0.0
0.0
0.0

(0.00)
(0.00)
(0.00)
(0.00)

-

82
158
24
24

(28.5)
(54.9)
(8.3)
(8.3)

-

0.0
0.0
82
62

(0.00)
(0.00)
(56.9)
(43.1)

707

101
113
42
32

(35.1)
(39.2)
(14,6)
(11.1)

281

48 (100)
0.0 (0.00)

1

253 (87.8)
35 (12.2)

1

0.0 (0.00)
0.0 (0.00)

-

41
35

(73.4)
(26.6)

142.2
93.4

18

25

16

(5.6)

23.4

0.0 (0.00)

-

31

(10.8)

85.9

0.0
0.0
0.0
0.0

-

0
48
48
48

(0.00)
(33.3)
(33.3)
(33.3)

-

(12.5)

(0.00)
(0.00)
(0.00)
(0.00)

-

Note. Hypertension and hyperglycemia were defined according to ATP III criteria (NCEP, 2002).
Obesity was defined according to WHO criteria (WHO, 2015). %= Percent, N=Number. Lam =
Lamivudine, Stav = Stavudine, Nvp = Nevirapine, Comb = Combivir, Efv = Efavirenz, Truv =
Truvada. SBP= Systolic blood pressure, DBP= Diastolic blood pressure.
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Results
Prevalence of Metabolic Syndrome Components
To identify the prevalence of hypertension, obesity, and hyperglycemia, I
excluded records of patients that showed baseline examination measurements within
hypertensive, obesity, and hyperglycaemic range. Thereafter, I used descriptive statistics
analysis to determine the prevalence of hypertension, obesity, and hyperglycemia. Total
prevalence for the pre- HAART and HAART groups are presented in Table 5. Moreover,
the prevalence of hypertension, obesity, and hyperglycemia stratified by gender and age
in the HAART regimen group are presented in Table 6. I used the chi-square test (χ2) for
independence to determine relationships between the duration of HAART regimen and
hypertension, duration of HAART regimen and obesity, duration of HAART regimen and
hyperglycemia using the 4 x 2 χ2 model.
The crosstabs I conducted were between HAART regimen for 6 months, 12
months, >12 months duration, and at baseline; and the presence or absence of each
dependent variable (hypertension, obesity, and hyperglycemia). Results are presented in
Table 7. The relationship between types of HAART regimen and metabolic syndrome
components is shown in Table 8. The relationship between metabolic syndrome
components and gender of patients on HAART is presented in Table 9, while the
relationship between metabolic syndrome components and age is shown in Table 10.
Odds ratios for hyperglycemia by type of HAART regimen is shown in Table 11.
Relationships between the type of HAART regimen and the individual components were
determined using χ2 and shown in Table 8. Statistically, significant associations were
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determined by a p = < .05. Variables with statistically significant associations were
further included in bivariate logistics regressions to determine the odds ratios (ORs) for
the individual variables. Results of the ORs are presented in Tables 11 and 12
respectively. After obtaining statistically significant ORs with each component, a final
model was run with each component adjusted for all covariates to identify the adjusted
effect of each independent variable on the dependent variables, while non-statistically
significant variables were excluded from the final model. Results of final model are
presented in Table 13.
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Table 5
Prevalence of Metabolic Syndrome Components in the Pre HAART and HAART Group

Variable

Pre-HAART

HAART

Value (N) Percent (%)

Value (N) Percent (%)

Hypertension

0.0

0.0

48

33.3

Obesity

18.0

12.5

16

5.6

0.0

0.0

31

10.8

Hyperglycemia

Note. Hypertension and hyperglycemia were defined by ATP III criteria (NCEP, 2002).
Obesity was defined according to WHO criteria (WHO, 2015).
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There was no prevalence (there were no cases) of hypertension and
hyperglycemia in the pre-HAART control group (Table 5). However, in the HAART
group, hypertension and hyperglycemia were 33.3% and 10.8% prevalent respectively
(Table 5). The prevalence of obesity in the control group and HAART groups were
12.5% and 5.6% respectively (Table 5). Obesity was 6.9% higher in the pre- HAART
control group than the HAART group (5.6%) (Table5).
In this study, the prevalence of hypertension in males (56.3%) is higher than in
females (43.8%) (Table 6). Similarly, males were more likely to become obese (15.0%)
than females (8.3%). Furthermore, hyperglycemia was 6% higher in males (25%) than in
females (19%). Results also showed that prevalence of hypertension increase with age. In
the 18─29 year age group, prevalence was 19.0% and in the 30─39 year group,
prevalence was 19.3%. Prevalence rose to 29.6% in the 40-50 group and nearly doubled
(58.3%) in the >50 year age group. Obesity prevalence was 8.8% in the 30-39 year age
group, 16.7% in the 40─50 age groups, and 16.7% in the >50 age group. However, there
was no obesity in the 18─29 age groups. Though hyperglycemia had a similar prevalence
trend as obesity, there was 19.0% prevalence of hyperglycemia in the age group 18─29.
Hyperglycemia prevalence was 17.5% in the age group 30-39; 27.8% in age group 40-5;
and 16.7% in the >50 age group (Table 6).
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Table 6
Metabolic Syndrome Components Prevalence in Patients on HAART Regimen by Gender
and Age
Variable

Gender
Male
Female
% (N ) % (N )

Age group (years)
18-29
30-39
40-50
% (N ) % (N ) % (N )

Hypertension

56.3 (27) 43.8 (21)

19.0 (4)

19.3 (11) 29.6 (16) 58.3 (7)

Obesity

15.0

8.3 (7)

00.0 (0)

8.8 (5) 16.7 (9)

19.0 (16)

19.0 (4)

(9)

Hyperglycemia 25.0 (15)

17.5 (10)

>50
% N

16.7 (2)

27.8 (15) 16.7 (2)

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %=
Percent, N= Number

78
Tables 7 and 8 present the relationships between duration of HAART regimen and
metabolic syndrome components and type of HAART regimen and metabolic syndrome
components respectively. At baseline, there were no cases of hypertension (0.00%),
obesity (0.00%), and hyperglycemia (0.00%). However, at six months, the prevalence of
hypertension was 10.4%; obesity was 4.2%, and hyperglycemia was 6.3%. Furthermore,
at 12 months on HAART regimen, the prevalence increased to 35.4% for hypertension,
12.5% for obesity, and 18.8% for hyperglycemia. Similarly, the prevalence of
hypertension and hyperglycemia were almost doubled with HAART regimen for >12
months (54.2% and 39.6%), respectively. However, obesity was 16.7% prevalent at >12
months (Table 7).
The χ2 (20.813) for hypertension and its corresponding p < .001 (Table 7) showed
that there was a statistically significant association between hypertension and duration of
HAART regimen. The effect size (Cramer’s V = 0.380) for the association was large. The
χ2 (24.353) and p < .001for obesity signified a statistically significant association
between obesity and duration of HAART regimen. The effect size of 0.54 was large
(Table 7). Similarly, χ2 for hyperglycemia was 63.08 and p < .001 also showed a
statistically significant association between hyperglycemia and duration of HAART
regimen. The effect size 0.468 was also large (Table 7).
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Table 7
Relationship Between Duration of HAART Regimen and Metabolic Syndrome
Components
Variable

Baseline
% (N )

6months
% (N )

12months
% (N )

>12months χ2
% (N )

p-value

Effect
size

Hypertension 0.00 (0) 10.4 (5)

35.4 (17)

54.2 (26)

20.813 <0.001*** 0.380

Obesity

4.2 (2)

12.5 (6)

16.7 (8)

24.354 <0.001*** 0.291

Hyperglycemia 0.00 (0) 6.3 (3)

18.8 (9)

39.6 (19)

60.91

0.00 (0)

<0.001*** 0.468

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %=
Percent, N= Number, χ2= Chi-square test, *** = Significant
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When stratified by types of HAART regimen, patients on the LAM, STAV, and
NVR regimen, 8.5% patients were obese, 20.7% were hypertensive, and 15.9% had
hyperglycemia. Also, with patients on the COMB, NVP regimen, 3.8% were obese, 9.5%
hypertensive, and 6.3% of the patients had hyperglycemia. Similarly, 4.2%, 12.5%,
12.5% of patients on the COMB, EFV regimen were obese, hypertensive, and had
hyperglycemia respectively. Furthermore, with the TRUV, EFV regimen, there was
obesity prevalence of 8.3%, hypertension was 12.5%, and hyperglycemia was 20.8%
(Table 8). The χ2 and p-values for hypertension, obesity, and hyperglycemia were (χ2 =
3.108, p = .375; χ2 = 2.761, p = .430; χ2 = 7.824, p = .045) respectively (Table 8).
Results showed that there were no statistically significant associations between
obesity and type of HAART regimen; hypertension and type of HAART regimen (p >
.05). However, there was a statistically significant association between hyperglycemia
and type of HAART regimen (p < .05) the association had a moderate effect size 0.167
(Table 8). Types of HAART regimen was not included in the final regression models for
hypertension and obesity because there was no statistically significant association
between types of HAART regimen and hypertension, and types of HAART regimen and
obesity. It is important to note here that where the assumption for Chi-square was
violated, the likelihood ratio was used instead as was the case for hyperglycemia.
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Table 8
Relationship Between Types of HAART Regimen and Metabolic Syndrome Components
Variable

Lam,stav,nvp

χ2

p- value Effect
size

Comb,nvp

Comb,efv

Truv,efv

% (N )

% (N )

% (N )

Hypertension 15.9 (13)

6.3 (10)

12.5 (3)

20.8 (5)

3.108 0.375

Nil

Obesity

20.7(17)

9.5 (15)

12.5 (3)

12.5 (3)

2.761 0.430

Nil

Hyperglycemia 8.5 (7)

3.8 (6)

4.2 (1)

8.3 (2)

7.824

% (N )

0.045* 0.167

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). %=
Percent, N= Number, χ2= Chi-square test, * = Significant, Lam=Lamivudine, stav=
Stavudine, nvp = Nevirapine, efv= Efavirenz, Truv= Truvada.
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Research Questions
The first research question was based on whether there is a relationship between
types of HAART regimen and metabolic syndrome components. The second research
question focused on whether there is a relationship between duration of HAART regimen
and metabolic syndrome components. To answer these research questions one and two, I
used the χ2 test to determine the associations between HAART regimen and metabolic
syndrome components and duration of HAART regimen and metabolic syndrome
components. I also used logistic regressions to identify bivariate odds ratio for
hypertension, obesity, and hyperglycemia with and without each covariate and
independent variable. This model was appropriate to determine the direction of the
association with each of the dependent variable (hypertension, obesity, and
hyperglycemia), and to determine if the independent variables were predictors of the
outcome, and to know the odds of developing hypertension, obesity, and hyperglycemia.
In addition, I used multiple logistics regression that included all covariates, but excluded
non-significant variables as the final model. Results of the final regression model are
presented in Table 13. All continuous variables were categorized. Results of the χ2 tests
are shown in Tables 7 and 8. The relationship between metabolic syndrome components
and gender of patients on HAART is presented in Table 9, while the relationship between
metabolic syndrome components and age of patients on HAART is shown in Table 10.
The bivariate logistic regression analyses are presented in Tables 11 and 12.
Results of the χ2 test showed that there was no statistically significant association
between types of HAART regimen and hypertension (χ2 = 3.108, p = .375 > .05, Table
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8). As a result, types of HAART regimen were excluded from the bivariate logistics
regression to determine odds of hypertension. Types of HAART regimen were also
excluded from the bivariate logistics regression to determine odds of obesity because
there was no significant association between types of HAART regimen and obesity (χ2 =
2.761, p = .430) (Table 8).
The relationship between metabolic syndrome components and gender of patients
on HAART is presented in Table 9. The Chi-square test for hypertension was 57.600 and
its corresponding p < .001. The χ2 showed that gender is statistically significantly related
to hypertension. The effect size for the association was large (0.447). Chi-square for
obesity was 16.941, p = .002, < .05. This indicated that gender was statistically
significantly related to obesity. The association also had a medium effect size (0.243).
Similarly, χ2 for hyperglycemia was 34.739, p-value < .001. This χ2 result implied that
gender is statistically significantly related to hyperglycemia. The effect size was 0.347
(Table 9). Results justified the inclusion of gender as a covariate in the final model.
The relationship between metabolic syndrome components and age of patients on
HAART is presented in Table 10. The χ2 test for hypertension was 55.122 and its
corresponding p < .001. This showed that age is statistically significantly related to
hypertension. The effect size for the association was large (0.425). Chi-square for obesity
was 21.510, p = 0.03, < .05 indicated that age was statistically significantly related to
obesity. The association had a medium effect size (0.221). Similarly, χ2 for
hyperglycemia was 33.740, p = < .001. This χ2 result implied that age is statistically
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significantly related to hyperglycemia. The effect size was 0.351 (Table 10). Results
justified the inclusion of age as a covariate in the final model.
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Table 9
Relationship Between Metabolic Syndrome Components and Gender of Patients on
HAART
Chi-square (χ2)/
Likelihood ratio

p-value

Effect size

Hypertension

57.600

< .001

0.447

S

Obesity

16.941

.002

0.243

S

Hyperglycemia

34.739

< .001

Variable

0.347

Significance

S

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S=
Significant,
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Table 10
Relationship Between Metabolic Syndrome Components and Age of Patients on HAART
Variable

Chi-square (χ2)/
Likelihood ratio

p-value

Effect size

Significance

Hypertension

55.122

< .001

0.425

S

Obesity

21.510

< .03

0.221

S

Hyperglycemia

33.740

< .001

0.351

S

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S=
Significant.
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ORs of hyperglycemia with the COMB and NVR; COMB and EFV; TRUV and
EFV regimen were 1.14 (95% CI, 0.526, 2.463); 3.11 (95% CI, 1.393, 6.944) and 1.13
(95% CI, 0.257, 5.00) respectively (Table 11). These ORs indicated that patients on
COMB and NVR regimen are 1.14 times odds of hyperglycemia, those on COMB and
EFV are 3.11 times odds of hyperglycemia, and those on TRUV and EFV 1.13 times
odds of having hyperglycemia, compared with patients on LAM, STAV, NVP (reference
group). Results showed that COMB and EFV regimen was statistically significantly
related to hyperglycemia (p = 0.006 < .05) (Table 11). However, I found COMB/ NVR
regimen and TRUV/ EFV regimen statistically not significantly related to hyperglycemia
(p = 0.742 and p = 0.867), respectively p > .05. Also, I could not predict the relationship
between LAM, STAV, NVP regimen and the dependent variables using the model.
The OR for hypertension at 12 months duration of HAART regimen was 3.10
(95% CI, 1.299, 7.352). This OR showed that patients are 3.10 times odds of developing
hypertension when on HAART regimen for 12 months. Odds ratio of 9.62 (95% CI,
3.205, 28.57) at >12 months indicated that patients on HAART for more than 12 months
are 9.62 times odds of developing hypertension. Results also showed that duration of
HAART was statistically significantly related to hypertension (p = .011< .05).
Furthermore, after controlling for the covariates, there were increases in the unadjusted
ORs for hypertension from 3.1(95% CI, 1.299, 7.352) (Table 12) to AOR = 4.15(95% CI,
1.949, 8.849) at 12 months and from OR 9.6 (95% CI, 3.205, 28.57) to AOR = 18.52 (CI,
5.464, 42.50) at >12 months (Table 13). Duration of HAART was still statistically
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significantly related to hypertension p < .001). The R2 was 0.498, signifying that 49.8%
of the variance could be explained.
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Table 11
Odds Ratio (OR) for Hyperglycemia by Types of HAART Regimen
Variable

Types of
HAART

OR(95% CI)

p- value

Sig

R2

Hyperglycemia
Lam,stav,nvp

referent

-

-

Comb,nvp

1.14 (0.526, 2.463)

0.742

NS

Comb,efv

3.11 (1.393, 6.944)

0.006

S

Truv,efv

1.13 (0.257, 5.000)

0.867

NS

0.816

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S=
Significant, NS= Not significant. OR=Odds ratio, CI= Confidence interval,
Sig=Significance, Lam=Lamivudine, stav= Stavudine, nvp = Nevirapine, efv= Efavirenz,
Truv= Truvada.
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Table 12
Odds Ratio (OR) for Metabolic Syndrome Components by Duration of HAART Regimen

Duration on
OR
95% CI
p- value
HAART (months)
Hypertension
Baseline
6
referent
12
3.1
1.299, 7.352
0.011
>12
9.6
3.205, 28.57
0.001
Obesity
Baseline
6
referent
12
1.71
0.590, 4.950
0.322
>12
5.95
1.284, 18.770
0.023
Hyperglycemia
Baseline
6
referent
12
2.23
0.910, 5.681
0.079
>12
8.33
2.283, 30.303
0.001
Variable

Sig

R2

S
S

0.498

NS
S

0.868

NS
S

0.816

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S=
Significant, NS= Not significant. OR=Odds ratio, CI= Confidence interval,
Sig=Significance
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ORs and corresponding confidence interval (CI) for obesity at 12 months and >12
months were 1.71(95% CI, 0.590, 4.950) and 5.95 (95% CI, 1.284, 27.77) respectively
(Table 12). These ORs show that obesity is 5.95 times more likely to develop when on
HAART for >12 months and 1.71 times more likely to develop when on HAART for 12
months. However, after controlling for gender, age, and CD4+ cell count, the OR for
obesity increased to AOR= 1.82 when on HAART for 12 months and increased to AOR
5.44 when on HAART for >12 months (Table 13). Statistically, HAART regimen for >12
months was significantly related to obesity (p = .023 < .05), whereas, HAART regimen
for 12 months only was statistically not significantly related to obesity (p = 0.322 > .05)
(Table 12). However, after adjustment for covariates, it resulted in statistical significance
at 12 months duration (p < .001). R2 was 0.868, showing that 86.8% of the variance could
be explained.
Hyperglycemia was 2.23 times odds of developing in patients on HAART for12
months (OR= 2.23, 95% CI, 0.910, 5.681) (Table 12) and 8.33 times odds of developing
in patients on HAART for >12 months (OR= 8.33, 95% CI, 2.283, 30.303) (Table 12).
However, after controlling for all the covariates, OR was nearly doubled (AOR= 3.91)
when on HAART for 12 months. Similarly, OR was nearly doubled (AOR= 14.71) when
on HAART for >12 months (Table 13). There was no prediction at baseline and 6
months. The results showed that gender, age, and CD4+ cell count have an influence on
the dependent variables. R2 of 0.816 showed that 81.6% of the variance could be
explained. Statistically, unadjusted OR of the group on HAART for 12 months was not
significant (p = .079), while the group on HAART for >12 months was statistically

92
significantly related to hyperglycemia (p = .001 < .05). Furthermore, after adjusting for
covariates, statistical significance was achieved for both groups. Consequently, I rejected
the null hypothesis and accepted the alternative hypothesis that duration of HAART
regimen increases the odds of hyperglycemia.
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Table 13
Adjusted Odds Ratio for Metabolic Syndrome Components by Duration of HAART
Regimen
Variable

Duration
on HAART

AOR (95% CI)

p- value

Sig

R2

Hypertension
Baseline
6
12
>12

referent
4.15
1.949, 8.849
18.52
5.464, 42.50

< .001
< .001

S
S

0.793

Baseline
6
12
>12

referent
1.82
4.349, 26.92
5.43
2.227, 13.158

< .001
< .001

S
S

0.835

Baseline
6
12
>12

referent
3.91
14.71

S
S

0.800

Obesity

Hyperglycemia
1.942, 9.259
4.425, 27.619

< .001
< .001

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S =
Significant, NS = Not significant. AOR= Adjusted odds ratio, CI= Confidence interval,
Sig = Significance.
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The relationship between immune statuses of patients measured by CD4+ T
lymphocyte and metabolic syndrome components is presented in Table 14. The χ2 test for
hypertension was 45.140 and its corresponding p < .001. This showed that CD4+ cell
count was statistically significantly related to hypertension. The effect size for the
association was large (0.396). Chi-square for obesity was 19.780, p-value = .003 < .05
indicated that CD4+ cell count was statistically significantly related to obesity. The
association also had a medium effect size (0.262). Similarly, χ2 for hyperglycemia was
27.327, p-value < .001. This χ2 result implies that CD4+ cell count is statistically
significantly related to hyperglycemia. The effect size was 0.308 (Table 14). The results
justified the inclusion of CD4+ T-lymphocyte count as a covariate in the final model.
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Table 14
Relationship Between Metabolic Syndrome Components and Immune Status of Patients
on HAART
Chi-square (χ2)/
Likelihood ratio

p-value

Hypertension

45.140

< .001

0.396

S

Obesity

19.780

.003

0.262

S

Hyperglycemia

27.327

< .001

0.308

S

Variable

Effect size

Significance

Note. Hypertension and hyperglycemia were defined according to ATP III criteria
(NCEP, 2002). Obesity was defined according to WHO criteria (WHO, 2015). S =
Significant, NS = Not significant.
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Summary
The characteristics of the population studied include gender, age, WHO HIV
disease staging, CD4+ T lymphocyte cell count, blood pressure measurement, body mass
index, and fasting blood sugar level in the pre-HAART control group and HAART group.
The variables were assessed at baseline and thereafter as recorded in their treatment
records. All the participants in the HAART group adhered to their regimen. Most of the
participants in the HAART group were in WHO disease stage < 3 at enrolment and a few
in WHO stages 3. Unlike the HAART group, all the participants in the pre-HAART
group at enrolment were in WHO disease stage 1. There were 59 males and 85 females in
the HAART group, whereas the pre-HAART group had 18 males and 30 females. The
mean value for age in the pre-HAART group was 35.25 years, and that of the HAART
group was 38.7 years. The average values for CD4+ cell count in the pre-HAART group
and HAART group were 707cells/mL and 281.6cells/mL respectively. I stratified the
HAART group into three according to the duration of HAART regimen. Each stratum
had 48 participants each at six months, 12 months, and >12 months. The HAART group
also had 82 participants on the Lamivudine, Stavudine, and Nevirapine regimen, 158 on
the Combivir and Nevirapine regimen, 24 participants each on Combivir and Efavirenz
regimen and Truvada and Efavirenz regimen.
In the determination of the prevalence of the metabolic syndrome components, I
found that 18 (12.5%) participants in the pre-HAART group were obese at baseline.
However, there were no cases of hypertension and hyperglycemia at baseline. The
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prevalence of systolic and diastolic hypertension was 73.4% and 26.6% respectively, and
the overall prevalence of hypertension was 16.7%.
I stratified the independent variables by types of HAART regimen and duration of
HAART regimen. I used the χ2 test for independence to examine the relationships
between the nonparametric variables. I also analyzed the bivariate odds of covariates
(age, gender, and CD4+ cell count); I then included only statistically significant variables
in the final model. The results showed that ORs differed by duration of HAART for all
components, but differed less for the types of HAART regimen. To control for the
potential influence of covariates on metabolic syndrome components, I included
covariates to the multiple logistic regression models that served as the final model. I used
multiple logistic regression analysis to assess odds ratios of types of HAART regimen
and duration of HAART regimen after controlling for all covariates. This was done to
determine whether these variables increased the odds of hypertension, obesity, and
hyperglycemia.
In this study, the odds of hypertension, obesity, and hyperglycemia increased with
duration of HAART, and I recorded statistical significance with hypertension in the
group on HAART for 12 months and the group on HAART for >12 months (p < .05). I
also recorded statistical significance with obesity and hyperglycemia in the group on
HAART for >12 months only (p < .05). However, there was no statistical significance
with obesity and hyperglycemia in the group on HAART for 12 months (p > .05). The
OR for hypertension at 12 months was 3.1 (95% CI, 1.299, 7.352, p < .05), at >12 months
OR was 9.6 (95% CI, 3.205, 28.57, p < .05). The OR for obesity at 12 months was 1.71
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(95% CI, 0.590, 4.950, p > .05), at >12 months OR was 5.95 (95% CI, 1.284, 18.770).
The OR for hyperglycemia at 12 months was 2.23 (95% CI, 0.910, 5.681, p > .05), at >12
months OR was 8.33 (95% CI, 2.283, 30.303, p < .05). Conversely, types of HAART
regimen did not increase odds of hyperglycemia. The OR for hyperglycemia with the
COMB, NVP regimen was 1.14 (95% CI, 0.526, 2.463), with the COMB, EFV regimen
OR was 3.11 (95% CI, 1.393, 6.944, p = .006), with the TRUV, EFV regimen OR was
1.13 (CI, 0.257, 5.000, p = .867). OR with HAART regimen was not done for
hypertension and obesity because of the no significant association results obtained with
the χ2 test.
The odds of hyperglycemia did not increase with the Combivir and Nevirapine
regimen (OR=1.14, 95% CI, 0.526, 2.463, p > .05) and the Truvada and Efavirenz
regimen (OR=1.13, 95% CI, 0.257, 5.000, p = .867). Only the Combivir and Efavirenz
regimen (OR=3.11, 95% CI, 1.393, 6.944, p = .006) achieved statistical significance and
increased the odds of hypertension, obesity, and hyperglycemia.
I accepted the null hypothesis (H0) for research question 1A that stated that
HAART regimen does not increase the odds of hypertension and rejected the alternative
hypothesis because of lack of statistical significance. Similarly, due to no statistically
significant relationship between types of HAART regimen and obesity, I accepted the
null hypothesis for research question 1B that stated that HAART regimen does not
increase the odds of obesity and rejected the alternative hypothesis. Furthermore, due to
no statistically significant relationship, I accepted the null hypothesis for research
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question 1C that stated that types of HAART regimen does not increase the odds of
hyperglycemia and rejected the alternative hypothesis.
For research question 2A, the results generated produced statistically significant
relationship to reject the null hypothesis in favor of the alternative hypothesis that stated
that duration of HAART regimen increases the odds of hypertension (AOR = 4.15, 95%
CI, 1.949, 8.849, p < .001) with the group on HAART for 12 months and AOR = 18.52
(95% CI, 5.464, 42.50) with the group on HAART for >12 months. I also rejected the
null hypothesis for research question 2B and accepted the alternative hypothesis that
stated that duration of HAART regimen increases the odds of obesity with respect to
duration of HAART for 12 months AOR=1.82 (95% CI, 4.349, 26.92, p < .001) and
HAART for >12 months (AOR= 5.43 (CI, 2.227, 13.158, p < .001). Furthermore, for
research question 2C, I accepted the alternative hypothesis that stated that duration of
HAART increases the odds of hyperglycemia and rejected the null because the result was
statistically significant (AOR =3.91, 95% CI, 1.942, 9.259, p < .001) at 12 months and
AOR = 14.71 (95% CI, 4.425, 27.619, p < .001) at >12 months.
In chapter 5, I interpret and discuss the results presented in this chapter. I
interpreted the results based on the metabolic theory and literature reviewed. I also
discuss the strengths and limitations of this study in Chapter 5. In addition, I present the
importance of the findings of this study to the population and recommend further indepth studies with primary data to validate the results of this study. I also discuss
recommendations for possible future intervention programs in chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
Discussion
The purpose of this study was to quantitatively analyze data from the treatment
records of HIV-positive individuals accessing treatment in the ART clinic in FMC,
Umuahia. I also determined whether HAART regimen and duration of HAART regimen
increased the odds of developing hypertension, obesity, and hyperglycemia in HIVpositive individuals. The aim of this study was to answer two research questions: (a) what
is the relationship among types of HAART regimen and hypertension, obesity, and
hyperglycemia as metabolic syndrome components in HIV-infected individuals?; (b)
what is the relationship among duration of HAART regimen and hypertension, obesity,
hyperglycemia as metabolic syndrome components in HIV-infected individuals? In
addition, I determined the prevalence of hypertension, obesity, and hyperglycemia among
HIV-positive individuals 18 years or older receiving treatment in the ART clinic in FMC
Umuahia.
In this study, I found a significantly high burden of hypertension (33.3%) and
hyperglycemia (10.8%) of the diabetic range among HIV-positive patients accessing
treatment in the ART clinic in FMC Umuahia. But obesity prevalence (5.6%) was not as
high. Hypertension, obesity, and hyperglycemia constitute major risk factors for CVD in
these groups of population (Chow et al., 2012; Guaraldi, et al., 2010; Palios, Kadoglou,
and Lampropoulos, 2012; Malangu, 2014; Muhammad et al., 2013; Zhou et al., 2014).
These risk factors, however, vary by population and racial differences (Ngatchou et al.,
2013).
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Metabolic syndrome components prevalence in HIV-infected individuals
associated with HAART regimen has been observed in cross-sectional observational
studies (Durang et al., 2011; Guaraldi, et al., 2010; Palios, Kadoglou, and Lampropoulos,
2012; Ngatchou et al., 2013). Before my study, there had been no report on the analysis
of the relationship between HAART regimen and metabolic syndrome components in
Umuahia metropolis. In this chapter, I interpret and discuss the findings presented in
Chapter 4. I also discuss the study limitations, the strength of the study, and
recommendations for further study based on the findings of this study. I also discuss the
implications for positive social change and public health practice, and the summary of the
key results of this study.
Interpretation of Findings
In this study, I used data from HIV- positive patients accessing treatment in FMC
Umuahia to provide information about the relationship among types of HAART regimen
and hypertension, obesity, and hyperglycemia; and the relationship among the duration of
HAART regimen and hypertension, obesity, and hyperglycemia. Information on the
prevalence of hypertension, obesity, and hyperglycemia among HIV-positive patients 18
years and older that were managed for HIV infection was also provided. The results of
this study showed that duration of HAART regimen is strongly related to hypertension
and hyperglycemia; less so with obesity and that hypertension tends to develop in
patients on HAART regimen for more than 12 months (OR = 9.6). Key findings of this
study confirmed suspicions that duration of HAART regimen increased the odds of
developing hypertension and hyperglycemia in HIV patients, and that the factors

102
associated with statistical significance were taking HAART regimen for more than 12
months.
Prevalence of Metabolic Syndrome Components
Hypertension and diabetes were defined according to the ATP III criteria (NCEP,
2002), while obesity was defined according to WHO criteria (WHO, 2015). The overall
prevalence of hypertension was 33.3%; that of hyperglycemia was 10.5%, and only 5.6%
obesity prevalence was recorded in this study. The results of this study are consistent
with previous prevalence reports on metabolic syndrome components (Berhane et al.,
2012; Denue et al., 2012; Dimodi et al., 2014). Similar to my study results, are the results
obtained by Gazzaruso et al. (2003) was 34.2% hypertension in patients on HAART.
Though the overall study population was relatively young (average age was 34.5
years in the pre-HAART group and 38.7 years average age in the HAART group),
hypertension, obesity, and hyperglycemia were more prevalent in the older age groups
than in the younger age groups. This result is consistent with the results of Muhammad et
al. (2013) who reported a mean age of 32.5 years in their study.
Metabolic syndrome components were more prevalent in males than in females in
this study, and prevalence also increased with age. This result is consistent with the
reports of Malangu (2014) that male patients were 2-fold more likely to have metabolic
syndrome compared to females.
Muhammad et al. (2013) evaluated the cardiovascular risks among patients on
HAART in a cross-sectional study amongst HIV patients placed on HAART for at least
six months, and HAART- naïve group in Aminu Kano Teaching Hospital, Nigeria. They
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compared the prevalence of metabolic syndrome components in the pre- HAART group
and the HAART group. Their result showed that the incidence of hypertension in patients
exposed to HAART regimen was approximately eight times higher than the non-exposed,
17% and 2% respectively (p < .001). Obesity prevalence of 2% and 11% was recorded in
the HAART naïve and HAART groups respectively and diabetes prevalence of 3% in
each of the two groups.
The study established significant correlations in cardiovascular risk factors such
as hypertension, obesity, diabetes, and hypercholesterolemia in patients treated with
HAART. But their results are not totally consistent with the results of this study. In my
study, I found higher obesity prevalence in the pre- HAART group (12.5%). However,
results obtained in this study are consistent to that obtained in the Data Collection on
Adverse Events of Anti-HIV Drugs (D. A. D) study where HAART naïve subjects were
more obese than the subjects on HAART. Akinboro, Onayemi, Ayodele, Mejiuni, and
Atiba (2013) also reported the presence of obesity 33.97±1.06 in the pre-HAART group
and no obesity in the HAART group. The recorded higher obesity prevalence in the preHAART group may have stemmed from the fact that patients in the pre- HAART group
had higher mean CD4+ cell count (707cells/ml), and were all at WHO HIV disease stage
1. At this stage, weight loss and other opportunistic infections had not set in compared to
the HAART group with mean CD4+ value of 281cells/ml. In contrast, our study did not
observe any hypertension and hyperglycemia prevalence in the pre- HAART group.
However, there was no statistically significant association between HAART regimen and
hypertension (χ2= 3.108, p = 0.375). Denue et al. (2012) and Muhammed et al. (2013) in
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their studies also reported a non-statistically significant relationship between HAART
and hypertension (p > 0.05).
All participants in the HAART group were on the 2NRTI plus 1 NNRTI regimen.
The regimens were in a cocktail of four different combinations as follows: (a)
Lamivudine, Stavudine, and Nevirapine (b) Combivir and Nevirapine (c) Combivir and
Efavirenz (d) Truvada and Efavirenz. None of the patients were on a PI containing
regimen. The pre- HAART control group had no patient on HAART. The development of
metabolic syndrome component is likely to be as a result of the exposure to HAART. But
the relationship that exist between the individual antiretroviral agent and metabolic
syndrome components is not clear.
In this study, the prevalence of hypertension was higher in patients on the
Truvada and Efavirenz regimen (20.8%), while obesity and hyperglycemia were observed
more in patients on the Lamivudine, Stavudine, and Nevirapine regimen (20.7%) and
(8.5%) respectively. However, there was no statistically significant association (p > .05)
between types of HAART regimen and metabolic syndrome components. This finding of
a non-statistically significant relationship between types of HAART regimen and
metabolic syndrome components is similar to the previous findings of Denue et al.
(2012). They found no statistical significance between classes of HAART and
hypertension.
In this study, the prevalence of the three metabolic syndrome components
increased with duration of HAART regimen. This result agrees with the report of
Berhane et al. (2012), where they found the duration of HAART to be independently
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associated with metabolic syndrome components. In their study, they found factors
associated with metabolic syndrome to be taking HAART for over twelve months.
Similarly, the effect of duration of HAART regimen was also reported by Malangu
(2014). Malangu indicated that prevalence of metabolic syndrome components was
higher as the length of treatment increased. This suggests that the use of HAART for
more than 12 months predisposes patients to develop metabolic syndrome.
Relationship Among Types of HAART Regimen, Duration of HAART Regimen and
Hypertension
Based on the total medical records of HIV-positive patients 18 years or older that
met the eligibility criteria, more than 30% of patients were hypertensive by ATP III
criteria that specified hypertension as systolic blood pressure measurement ≥130 and a
diastolic blood pressure measurement ≥85mm Hg (NCEP, 2002). The ≥130/85 mm Hg
range implies an increasing blood pressure that can reach the categorical level for
hypertension since hypertension is a progressive condition. The 33.3% recorded in this
study was higher than the 15.9% reported by Sachithananthan et al. (2012) in Ethiopia.
Prevalence was higher among males (56.3%) and the group older than 50 years (58.3%).
This result is consistent with previous research results by Malangu (2014) and Denue et
al. (2012). To determine if the relationship between HAART regimen and hypertension
and the relationship between duration of HAART regimen and hypertension are
statistically significant, I used the χ2 test of independence. The χ2 for types of HAART
regimen and hypertension (3.108, p = 0.375) suggested that there was no association
between HAART regimen and hypertension. Muhammed et al. (2013) reported similar
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findings in a previous study that HAART was not statistically significantly associated
with hypertension. However, χ2 (20.813, p < .001) for duration of HAART and
hypertension showed that there is an association. The effect size (0.380) signifies a large
effect size. Further bivariate logistic regression analysis revealed that hypertension was
more than 3 times (OR= 3.10, 95% CI, 1.299, 7.352) likely to develop in patients on
HAART for 12 months, and more than 9 times (OR 9.62, 95% CI, 3.205, 28.57) as likely
for patients on HAART for more than 12 months, compared with patients on HAART
regimen for less than 12 months.
Despite the increase in ORs by more than one fold and more than 8-fold after
controlling for covariates, statistical significance for hypertension was still maintained for
the duration of HAART for 12 months and >12 months respectively. As a result, the null
hypothesis that duration of HAART does not increase the odds of hypertension was
rejected. Denue et al. (2012) reported similar results. Their study examined the impact of
HAART on blood pressure after two years of commencement of HAART in a cohort of
227 HIV patients. Their results showed a rise in blood pressure with time. The study by
Arruda Junior et al. (2010) also is consistent with our results. Furthermore, this study
demonstrated that the significant increase in OR for hypertension when all covariates
were controlled, indicated that the actual independent effect of duration of HAART on
hypertension was not confounded by age, gender, and CD4+ cell count.
Relationship Among HAART regimen, Duration of HAART Regimen and Obesity
Using the WHO definition of obesity, I considered BMI ≥30 kg/m2 obese, and
regarded BMI ≤ 30 kg/m2 as not obese. The literature reviewed showed that exposure to
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HAART affects body fat distribution in HIV-infected patients and also increases the risk
of CVD (Brown et al., 2009). Based on the above definition of obesity, this study showed
overall obesity of 5.6% and χ2 for HAART regimen and obesity was 2.761, p = .430. This
result implies that the association between obesity and HAART regimen is not
statistically significant.
Due to the inability to observe a significant association between HAART regimen
and obesity, HAART regimen was excluded from the subsequent logistics regression
models. As a result of the insufficient evidence to accept the alternative hypothesis, the
null hypothesis that HAART regimen does not increase the odds of obesity was accepted.
Muhammed et al. (2013) reported similar findings of no association between obesity and
HAART regimen. While this study was unable to establish that HAART regimen
statistically significantly increased odds of obesity, several other studies did observe
statistical significance (Dimodi et al., 2014; Jacobson, Tang, Spiegelman, Thomas,
Skinner, Gorbach, et al., 2006; and Wu et al., 2012). Conversely, there was a statistically
significant association between obesity and duration of HAART (χ2 = 24.354, p < .001).
Further bivariate logistic regressions analysis produced results that supported the
association between duration of HAART and obesity. ORs indicated that obesity is nearly
2 folds (OR= 1.71, 95% CI= 0.590, 4.950) more likely in patients on HAART regimen
for 12 and more than 5 folds (OR= 5.95, 95% CI= 1.284, 27.77) more likely in patients
on HAART regimen for >12 months, respectively. This result is consistent with the
findings of Sharma et al. (2014) where they reported statistical significance p < .05
between duration of HAART and obesity. However, adjusting for covariates increased
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the ORs by more than a fold for patients on HAART for 12 months (AOR= 4.15, 95%
CI, 1.949, 8.849), and increased the OR by more than 8 fold for patients on HAART for
>12 months (AOR = 18.52, 95% CI, 5.464, 42.50) on HAART, respectively.
Relationship Among HAART Regimen, Duration of HAART Regimen and
Hyperglycemia
Diabetes was defined according to the ATP III definition of fasting blood glucose
>100mg/dl (NCEP, 2002). However, due to the absence of other diabetes mellitus indices
such as Hb A1C test results in patients’ records, I chose to use the term hyperglycemia
instead. Like hypertension, type 2 diabetes mellitus is a progressive condition. Elevated
blood glucose (hyperglycemia) is a marker for insulin resistance, which together with
glucose intolerance lead to chronically high circulating blood sugars which subsequently
results in diabetes mellitus (Reaven, 1988; Schneider, 2014). Based on the definition,
overall hyperglycemia in this study was 10.5%. This result is similar to the 8% reported
by Sachithananthan et al. (2012) in Ethiopia. In examining the relationship between
HAART and hyperglycemia and the relationship between duration of HAART and
hyperglycemia, χ2 = 0.167, p = .045 and χ2 = 63.08, p < .001 were obtained for HAART
regimen and duration of HAART regimen, respectively. These associations were
statistically significant with medium (0.167 for HAART) to large (0.468 for the duration
on HAART) effect size, respectively.
Further bivariate logistic regressions showed odds of hyperglycemia was more
than two folds at 12 months (OR= 2.23, 95% CI= 0.910, 5.681) and more than 8-fold at
>12 months (OR= 8.33, 95% CI= 2.283, 30.303). There was no statistical significance at
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12 months before adjustment. However, adjusting for covariates increased OR by nearly
2-fold (AOR= 4.15) and statistical significance at 12 months (p < .001). Also, after taking
age, gender, and CD4+ cell count into account in subsequent analyses to control for their
influence, HAART regimen at >12 months OR dropped by more than 6-fold (AOR=
1.82), but maintained statistical significance (p < .001). Thus, there was sufficient
evidence to reject the null hypothesis and accept the alternative hypothesis that duration
of HAART regimen increases the odds of hyperglycemia. Abebe et al. (2014) reported a
similar result in their study conducted in Ethiopia, where they examined the association
between antiretroviral treatment and hyperglycemia and dyslipidemia. Diouf et al. (2012)
in Senegal also reported associations between prolonged exposure to HAART and
diabetes. However, Hansen et al. (2009) had a different report of no association between
presence of metabolic syndrome and HAART duration in Denmark.
The reference point for significance in this study was p < .05 and the decision to
accept the null hypotheses for each sub-question were based on this reference point,
while failure to reach statistical significance was set at the 95% confidence interval (CI).
The 95% CI in all the models used implied that the odds in those with hypertension,
obesity, and hyperglycemia fell within the ranges of the confidence interval 95% of the
time.
To minimize the possibility of a type II error, I interpreted the p-values taking into
consideration the confidence intervals (CI). I also interpreted practical significance based
on the effect sizes. It is noteworthy to say that the effect sizes obtained in this study were
moderate to large. The medium to large effect size implied that the effect sizes are
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sufficient to be of practical significance. The statistical and practical significance in the
models supports the application of metabolic syndrome theory to the prevalence of
hypertension, obesity, and hyperglycemia in this population. Lack of statistical
significance in some cases may be that sample size was not big enough and did not
necessarily mean that there was no association.
Regarding practical significance of the findings, the effect of duration of HAART
on obesity, hypertension, and hyperglycemia was moderate to large (effect size for
obesity = 0.291, for hypertension = 0.380, and for hyperglycemia = 0.468). This result
showed that duration of HAART supports the metabolic syndrome theory with the
covariates adjusted. Thus, going by the metabolic syndrome theory, development of
hypertension, obesity, and type 2 diabetes mellitus is an integrated and multi-staged
process that involves several metabolic processes.
Also, the inability to establish an association between HAART regimen and the
metabolic syndrome components and failure to link NRTIs and NNRTI to the metabolic
syndrome components could be due to the reason that only NRTIs and NNRTIs and no
PIs drug combinations were used. This is supported by reports of other researchers that
metabolic abnormalities are less likely to occur with NNRTI drug combinations (Hansen
et al., 2009; Muhammed et al., 2013; Wu et al., 2012).
Although causal relationships between HAART and hyperglycemia, obesity, and
hyperglycemia could not be established in this study due to the nature of study design,
information on the temporal associations upon which other studies can build was
provided. This study also increases the body of knowledge. Results are pointers to the
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fact that the length of time a patient is on HAART affect the metabolism of lipid and
glucose, as well as the functions of adipose tissue. This effect on metabolism
significantly influences metabolic syndrome in HIV patients on HAART regimen. Thus,
in this study, HAART regimen for more than 12 months increased the odds of
hypertension more than 9-fold; increased the odds of obesity more than 5-fold, and
increased the odds of hyperglycemia more than 8-fold before adjustment. However, after
adjusting for covariates, HAART regimen for more than 12 months increased the odds of
hypertension more than 8-fold; decreased the odds of obesity one- fold, and increased the
odds of hyperglycemia by more than six-fold.
The confidence intervals obtained were fairly wide, but most of the results have
intervals higher than 1.0. The high interval indicates the observed associations are truly
significant, and, with a larger sample size, the interval would be narrowed.
Association Between Immune Status and Metabolic Syndrome Components
CD4+ cells are white blood cells that are vital and play significant role in the
immune system (AIDS.gov, 2015). The CD4+ cell counts are used to monitor the
immune status and disease progression in HIV patients. CD4+ cell count is a significant
indicator of how well the immune system is (AIDS.gov, 2015). The normal CD4+ cell
count for healthy adults and adolescents is between 500 cells/ml and 1,200 cells/ml. HIVinfected individuals are usually initiated to commence HAART treatment when the count
is < 350 cells/ml. There are conflicting reports on the association between CD4+ cell
count and metabolic syndrome. While some previous studies found no association (Worm
et al., 2009), other cross-sectional studies found that higher CD4 + cell count increased
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the risk for metabolic syndrome (Alvarez, Salazar, & Galindez, 2010). Another crosssectional study found a different result of low CD4+cell count < 100 cells/ml to be
associated with higher risk of metabolic syndrome (Bonfanti, De Socio, Marconi, et al.,
2010). This study however found statistically significant associations between CD4+ cell
count and hypertension (χ2 = 45.140, p < .001), obesity (χ2 =14.117, p < .05), and
hyperglycemia (χ2 = 25.702, p < .001). Their effect sizes were moderate to large. This
result thus justified my inclusion of CD4+ as a covariate in the final model.
In this study, being male, older age, and duration of HAART regimen were
factors associated with developing hypertension, obesity, and hyperglycemia. Though not
all the findings were statistically significant, this study is consistent with findings from
previous similar studies. Comparing results of this study with results obtained in other
populations regarding metabolic syndrome is a bit difficult. It is difficult because there
are differences in methods, study designs, and data collection, as discussed in Chapter 2.
There are no other similar studies that used secondary data, same methods, and design
within this population with which to compare findings. Similar studies in other parts of
Nigeria (northeast and the southwest) differed in study design and methods (Denue et al.,
2012; Muhammed et al., 2013). They used primary data for their studies so did Berhane's
et al study in Ethiopia.
In summary, this study is the first study to examine the relationship among
HAART regimen and hypertension, obesity, and hyperglycemia; duration of HAART
regimen and hypertension, obesity, and hyperglycemia in HIV patients in Umuahia
metropolis. The odds of hypertension were more than 4-fold when on HAART for 12
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months and more than 18-fold when on HAART for >12 months, compared to HIV
patients on HAART for less than 12 months, after adjusting for covariates. Similarly,
odds of obesity were nearly 2-fold when on HAART for 12 months and more than 5-fold
when on HAART for >12 months. Similarly, odds of hyperglycemia were more than 3fold when on HAART for 12 months and more than 14-fold when on HAART for >12
months. Statistical significance was achieved in the analyses of HAART duration on
hypertension, obesity, and hyperglycemia after controlling for covariates. Regardless of
the significant findings, this study has some limitations that are worthy of mention. I
discuss these limitations in the following section.
Limitations
The first limitation of this study was the incomplete capture of patient’s data in
the treatment care cards. Information such as family history of diabetes and hypertension
were not recorded. Also not recorded was information on cigarette smoking, alcohol use,
and socioeconomic status. These are possible confounders shown by other studies to be
associated with metabolic syndrome (Alvarez, Salazar, Galindez et al., 2010). A second
limitation was that the hemoglobin A1C (HbA1C) test which is a more reliable method of
diagnosing diabetes was not recorded; similarly, there was no information on the use of
anti-hypertensive and anti-diabetic medications.
Since there were no sufficient indices for diabetes mellitus diagnosis, I decided to
use only the fasting blood sugar (FBS) test report. Hence, I used the term hyperglycemia
instead of diabetes mellitus where FBS was ≥100mg/dL. The third limitation was that
there was no information on lipid profile in patients’ records. As a result, low-density
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cholesterol and triglycerides assessment which are known risk factors from literature
could not be assessed. The fourth limitation was that only NRTI and NNRTI-based
regimens were used, and no PI-based regimens were used.
Despite the strength of this study in the stratified method of sampling that should
minimize bias and promote generalizability, the study results may not be generalizable
beyond the study population because metabolic syndrome components differ by race,
ethnicity, and region (Narayanan et al., 2010). Also, because of the limitations detailed
above, the internal validity of my study results may be influenced. However, despite
these limitations, some significant findings that are consistent with other cross-sectional
and association studies were recorded. The validity of the metabolic syndrome
components was supported by the ATP III criteria used to define hypertension and
hyperglycemia and WHO criteria used to define obesity. Hypertension, obesity, and
hyperglycemia were measured laboratory values that used gold standards and were
recorded on the individual patients’ treatment care cards. The values were continuous and
later dichotomized to reflect the presence or absence of each of the component.
Conclusion
The length of time an HIV-infected patient is on the HAART regimen
significantly increased the odds of hypertension, obesity, and hyperglycemia. The odds
are further increased when patients are older and are males. On the other hand, being on
NNRTIs and NRTIs-based regimen alone did not increase the odds of hypertension,
obesity, and hyperglycemia. In this study, prevalence of hypertension was higher than
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prevalence rates recorded for obesity and hyperglycemia. Prevalence also increased with
age, length of time on HAART, and higher in males.
This study showed that while the immune statuses of patients were being
improved through HAART regimen, patients were being predisposed to developing
hypertension, obesity, and hyperglycemia. As a result, there is a need to assess HIV
patients periodically for cardiovascular risk factors while on the regimen. Periodic
assessment will ensure early detection and proper management of the risk factors and
prevent the additional burden of heart disease. Thus, there is a need to create population
awareness of the risks posed by being exposed to HAART regimen for a longer duration.
There is also need to develop and implement lifestyle intervention programs for the HIVpositive population undergoing anti-retroviral therapy in Umuahia metropolis.
Recommendations
Given the limitations of this study, and being the first study of this nature in
Umuahia metropolis, a prospective study with primary data should be conducted to
confirm these results. Data should include all the possible known confounders such as
cigarette smoking, alcohol use, type of diet, physical activities, the use of antihypertensive and anti-diabetic that were not recorded in patients’ medical records.
Furthermore, because of the findings of this study that hypertension, obesity, and
hyperglycemia increased with age, being male, and duration of treatment, I at this
moment recommend that HIV patients on HAART regimen be monitored periodically for
high blood pressure, obesity, and hyperglycemia. The periodic monitoring will make
room for necessary control and management of the metabolic syndrome components,
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especially in the older males. It is pertinent to note that metabolic syndrome components
and the risk factors for metabolic syndrome are modifiable. As a result, lifestyle/behavior
change intervention programs are advisable for HIV patients on HAART regimen.
My findings provide population-based evidence that can be used by decision
makers such as WHO, United States Agency for International Development (USAID),
National Agency for the Control of AIDS (NACA), State Agency for the Control of
AIDS (SACA), and the management of the Federal Medical Centre, Umuahia for policy
making. Also, publishing findings will contribute to the wealth of scientific knowledge.
There is the need for more studies to confirm the effects of specific risk factors and
covariates such as length of time on HAART regimen, CD4+ cell count, age and sex that
appeared to confer risk differently in HIV-infected patients.
Implications
In this study, the length of time a patient was placed on the HAART regimen
played a significant contributory role in the prevalence of hypertension, obesity, and
hyperglycemia. This has important implications for, metabolic syndrome theory, health
care practice, and positive social change in this population.
Implications for Metabolic Syndrome Theory
Despite differences in study aims, design, and methods, results of this study are
consistent with previous studies in similar populations, as well as other populations. The
results also strengthened the general concept of the metabolic syndrome theory. Thus,
metabolic syndrome components not only occur together, but their co-occurrence while
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on HAART for more than 12 months was statistically significant as measured after
adjusting for gender, age, and CD4+ cell count.
Findings of this study showed that being on HAART regimen for more than 12
months conferred the most risk for hypertension, obesity, and hyperglycemia; and the
risks increased with older age, being male and lower CD4+ cell count. This expansion of
the metabolic syndrome theory is supported by other studies (Alvarez, Salazar, Galindez
et al., 2010; Bonfanti et al., 2010; Dimodi et al., 2014; Malangu, 2013).
Implications for Health Care Practice
In this study, the population-based evidence of risk factors that contribute to
hypertension, obesity, and hyperglycemia were shown. These evidence-based risk factors
can be taken into consideration by health care providers while caring for patients in this
population. Findings in this study support the initiation of and periodic screening for
hypertension, obesity, and hyperglycemia in HIV patients on HAART especially when
they are older. The periodic screening will help to prevent occurrence of metabolic
syndrome components. Also, efforts geared towards disease prevention should focus
more attention on blood pressure, BMI, lipids, and fasting blood glucose measurements.
This is because early detection and management can go a long way in preventing CVD,
thereby preventing additional disease and financial burden on this population group.
Though weight is routinely checked during clinic visits and height taken only at
enrolment, the BMI was not calculated to screen for obesity. Thus, this should be
addressed by health care providers. Also to be addressed by health care providers is the
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inclusion of lipid profile tests as part of the routine tests conducted to enable assessment
of the lipid profile of HIV patients while on HAART regimen.
Implications for Positive Social Change
Access to the findings of this study by HIV-infected patients through health talks
or population-based intervention programs will equip them with knowledge of the risk
factors for hypertension, obesity, and diabetes. By reducing the prevalence of metabolic
syndrome components, the risk for CVD, diabetic complications such as blindness and
amputation of the lower limbs, and kidney failure will be significantly reduced.
Knowledge of study findings will also reduce or eliminate additional medical expenses
caused by hospitalization as a result of chronic diseases, thereby improving the overall
health and quality of life of this population. Furthermore, loss of income through reduced
productivity as a result of ill health will also be minimized.
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